Cost-Effectiveness of Alternative Management Strategies for Patients with Solitary Pulmonary Nodules

Michael K. Gould; Gillian D. Sanders; Paul G. Barnett; Chara E. Rydzak; Courtney C. Maclean; Mark B. McClellan; Douglas K. Owens

doi:10.7326/0003-4819-138-9-200305060-00009

Academia and the Profession |6 May 2003

Cost-Effectiveness of Alternative Management Strategies for Patients with Solitary Pulmonary Nodules Free

Michael K. Gould, MD, MS; Gillian D. Sanders, PhD; Paul G. Barnett, PhD; Chara E. Rydzak, BA; Courtney C. Maclean, BA; Mark B. McClellan, MD, PhD; Douglas K. Owens, MD, MS

Article, Author, and Disclosure Information

Abstract

Background:

Positron emission tomography (PET) with 18-fluorodeoxyglucose (FDG) is a potentially useful but expensive test to diagnose solitary pulmonary nodules.

Objective:

To evaluate the cost-effectiveness of strategies for pulmonary nodule diagnosis and to specifically compare strategies that did and did not include FDG-PET.

Design:

Decision model.

Data Sources:

Accuracy and complications of diagnostic tests were estimated by using meta-analysis and literature review. Modeled survival was based on data from a large tumor registry. Cost estimates were derived from Medicare reimbursement and other sources.

Target Population:

All adult patients with a new, noncalcified pulmonary nodule seen on chest radiograph.

Time Horizon:

Patient lifetime.

Perspective:

Societal.

Intervention:

40 clinically plausible combinations of 5 diagnostic interventions, including computed tomography, FDG-PET, transthoracic needle biopsy, surgery, and watchful waiting.

Outcome Measures:

Costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios.

Results of Base-Case Analysis:

The cost-effectiveness of strategies depended critically on the pretest probability of malignancy. For patients with low pretest probability (26%), strategies that used FDG-PET selectively when computed tomography results were possibly malignant cost as little as $20 000 per QALY gained. For patients with high pretest probability (79%), strategies that used FDG-PET selectively when computed tomography results were benign cost as little as $16 000 per QALY gained. For patients with intermediate pretest probability (55%), FDG-PET strategies cost more than $220 000 per QALY gained because they were more costly but only marginally more effective than computed tomography-based strategies.

Results of Sensitivity Analysis:

The choice of strategy also depended on the risk for surgical complications, the probability of nondiagnostic needle biopsy, the sensitivity of computed tomography, and patient preferences for time spent in watchful waiting. In probabilistic sensitivity analysis, FDG-PET strategies were cost saving or cost less than $100 000 per QALY gained in 76.7%, 24.4%, and 99.9% of computer simulations for patients with low, intermediate, and high pretest probability, respectively.

Conclusions:

FDG-PET should be used selectively when pretest probability and computed tomography findings are discordant or in patients with intermediate pretest probability who are at high risk for surgical complications. In most other circumstances, computed tomography-based strategies result in similar quality-adjusted life-years and lower costs.

The solitary pulmonary nodule is a single, well-circumscribed, spherical radiographic opacity that measures less than 3 to 4 cm in diameter and is surrounded completely by aerated lung (1). There is no associated atelectasis, hilar enlargement, or pleural effusion. Most pulmonary nodules are discovered incidentally on chest radiographs, and 15% to 75% of such nodules are malignant, depending on the population studied (2, 3). Patients with pulmonary nodules and their physicians confront difficult decisions about the risks and rewards of different management strategies. When present, malignancy must be promptly identified to permit timely resection.

Pulmonary nodule evaluation typically begins with imaging studies. Computed tomography (CT) localizes the nodule within the lung parenchyma, and CT density characteristics sometimes indicate occult calcification that suggests a benign cause (4). Other CT findings, such as spiculation, are strongly associated with malignancy (5). Positron emission tomography (PET) with the glucose analogue 18-fluorodeoxyglucose (FDG) identifies malignant tumors on the basis of their increased metabolic rate. The use of FDG-PET is rapidly gaining acceptance in clinical oncology to diagnose tumors, stage disease, and evaluate treatment response (6, 7). Because FDG-PET is believed to be highly sensitive for identifying malignant nodules, proponents argue that observation with serial chest radiographs is safe when PET results are negative (8).

Management alternatives for patients with pulmonary nodules include surgical resection, transthoracic needle biopsy, and watchful waiting (9). Surgery is the diagnostic gold standard and the definitive treatment for malignant nodules that are resectable, but surgery should be avoided in patients with benign nodules. Needle biopsy often establishes a specific malignant or benign diagnosis, but biopsy is invasive, potentially risky, and frequently nondiagnostic. Watchful waiting avoids unnecessary surgery for benign nodules but may delay diagnosis and treatment of malignant nodules.

We developed a decision analytic model to identify the most effective approaches to diagnose and manage solitary pulmonary nodules. We performed a cost-effectiveness analysis to quantify the health effects and economic costs associated with various management strategies. Because of the considerable recent interest in the use of FDG-PET, we specifically compared diagnostic strategies that used FDG-PET with strategies that did not include this potentially useful but expensive test.

Methods

We performed a cost-effectiveness analysis by following the recommendations of the Panel on Cost-Effectiveness in Health and Medicine for conducting and reporting a reference-case analysis (10). The analysis adopted a societal perspective that would permit comparisons across different health care interventions. We expressed our results in terms of costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. All costs and health effects were discounted at an annual rate of 3%. Additional details on our methods, data sources, and results can be found in the Appendix. An electronic decision aid that is based on our results will be available at www.annals.org in July 2003.

Clinical Problem

The target population for this analysis was all adult patients with a new, noncalcified solitary pulmonary nodule on chest radiograph and no known extra-thoracic malignancy. Our base-case analysis considered a hypothetical cohort of 62-year-old men and women.

Decision Model Structure and Assumptions

We considered 40 clinically plausible sequences of five diagnostic interventions: CT, FDG-PET, transthoracic needle biopsy, surgery, and watchful waiting (Appendix Figures 1 and 2. We assumed that CT and FDG-PET were never performed after needle biopsy or surgery because performing an imaging test after an invasive diagnostic procedure is unusual. Similarly, needle biopsy and observation were never performed after surgery.

Needle biopsy was considered to be nondiagnostic unless a specific benign or malignant diagnosis was obtained. We assumed that surgery would be performed if the biopsy revealed malignancy. If the biopsy revealed a specific benign diagnosis, the patient would be managed accordingly. After a nondiagnostic needle biopsy, either surgery or watchful waiting could be selected as the next diagnostic intervention.

A final diagnosis was established at the time of surgery or, alternatively, after 24 months of observation. In the watchful waiting strategy, serial chest radiographs were obtained at 1, 2, 4, and 6 months and every 3 months thereafter. We assumed that surgery would be performed if nodule growth was observed at any time. If no growth was observed after 24 months, we assumed that the nodule was benign.

Modeling Long-Term Costs and Clinical Outcomes

We developed a Markov model to estimate long-term outcomes and costs for patients with malignant and benign pulmonary nodules (Appendix Figure 3). The model followed patients in the hypothetical study cohort over their remaining life span. We estimated the monthly probability of cancer recurrence after surgical treatment for patients with malignant nodules by using survival data from the Surveillance, Epidemiology and End Results (SEER) tumor registry (11). We used SEER data and a model of the natural history of untreated lung cancer to estimate the probability of disease progression in patients with malignant nodules who were managed by watchful waiting.

Data and Assumptions

We derived estimates for patient and nodule characteristics, diagnostic testing variables, costs and utilities from clinical and administrative sources (Appendix Table 1).

Patient and Nodule Characteristics

In the base-case analysis, we assumed that the pulmonary nodule measured 2 cm in diameter. We assumed that 12.5% of patients with malignant nodules would have regional lymph node involvement, the median prevalence of mediastinal metastases in eight studies of CT for staging in patients with T1 tumors (12-19). We derived the distribution of tumor growth rates for patients with malignant nodules from the Veterans AdministrationArmed Forces Cooperative Study on Asymptomatic Pulmonary Nodules (20).

Pretest Probability

We performed separate analyses for representative patients with low (26%), intermediate (55%), and high (79%) pretest probabilities of malignancy. Although most clinicians assess this intuitively, investigators have developed quantitative models to estimate the probability of cancer. One model that has undergone preliminary validation used logistic regression to identify six independent predictors of malignancy: age, smoking status, history of cancer, nodule diameter, spiculation, and upper lobe location (21). Additional information about this model, including the prediction equation, can be found in the Appendix.

Diagnostic Test Performance

We performed a meta-analysis to estimate the diagnostic accuracy of FDG-PET; our methods and results have been published elsewhere (22). We identified 13 studies of FDG-PET that enrolled 450 patients with pulmonary nodules (23-35). We used the method of Moses and colleagues (36, 37) to construct a summary receiver-operating characteristic (ROC) curve for FDG-PET. For our base-case estimates, we selected an operating point on the ROC curve that corresponded to the median specificity of FDG-PET in the 13 studies. At this point on the curve, sensitivity and specificity for identifying malignancy were 94.2% and 83.3%, respectively.

To estimate diagnostic performance for CT and transthoracic needle biopsy, we searched MEDLINE and applied Moses and colleagues' method to construct summary ROC curves for these tests. For CT, base-case estimates of sensitivity and specificity for identifying malignancy were 96.5% and 55.8%, respectively (2-4, 38-47). In this report, the terms possibly malignant and benign describe CT results that are positive and negative for malignancy, respectively.

We estimated that CT-guided needle biopsy would not reveal a specific diagnosis in 8% of patients with malignant nodules and 44% of patients with benign nodules (27, 48-55). When fluoroscopic guidance was used, we assumed that the frequency of nondiagnostic biopsy results would be 10% higher (56-58). When needle biopsy revealed a specific benign or malignant diagnosis, we estimated that the false-negative and false-positive rates were 3.7% and 2.0%, respectively (27, 48-55). Base-case estimates of the probability of minor pneumothorax and major pneumothorax requiring chest tube drainage were 24% and 5%, respectively (27, 48-55).

We assumed that video-assisted thoracoscopy would be used to perform surgical biopsy and that the procedure would be converted to a thoracotomy with lobectomy if the frozen section revealed malignancy. We derived estimates for probabilities of fatal and non-fatal surgical complications from sources in the clinical literature (59-67).

Costs

We converted all costs to 2001 U.S. dollars by using the gross domestic product deflator (68, 69). To derive costs for imaging tests and needle biopsy, we added procedure costs and professional fees that were based on Medicare reimbursement rates (70, 71). To estimate costs for surgical procedures and complications, we added professional fees (70) and median cost-adjusted charges from the 1996 Health Care Utilization Project database (72). To estimate long-term costs for patients with local, regional, and distant-stage lung cancer, we analyzed Medicare claims files linked with data from the SEER tumor registry for the years 1990 to 1993 (73). To estimate health care costs for patients with benign nodules and for patients with malignant nodules who survived more than 5 years after diagnosis, we used age-specific, annual health care expenditures from the Consumer Expenditures Study (74).

Utilities

We adjusted life expectancy for quality of life by using age- and sex-specific utilities (preference-based weights for health states) from the Beaver Dam Health Outcomes study (75) and available data to estimate reductions in utility associated with regional and distant-stage lung cancer (76). We also adjusted life expectancy for time spent in the hospital and time spent having diagnostic procedures. When possible, we used data on average length of hospital stay to make these adjustments (71). Because we could not identify studies that measured utilities in patients with undiagnosed pulmonary nodules, we assumed that the relative utility for time spent during observation was normal and we used age- and sex-specific values. To account for the possibility that some patients might be uncomfortable not knowing whether a nodule was benign or malignant, we tested lower values in a sensitivity analysis.

Sensitivity Analysis

One-way, multiway, and probabilistic sensitivity analyses were performed to identify important model uncertainties. When possible, ranges for variables were based on reported or calculated 95% CIs for means and interquartile ranges for medians. For diagnostic accuracy, several points on summary ROC curves and their 95% confidence intervals were evaluated. Clinical judgment was used to determine ranges for utilities. For costs, ranges were determined by adding or subtracting 25% from the base-case estimate. To determine ranges for transition probabilities in the Markov model, 50% was added or subtracted from the base-case value because these estimates were highly uncertain.

We performed probabilistic sensitivity analysis by stratifying patients according to pretest probability and risk for surgical complications. We assigned logit-normal distributions to all costs and probabilities for all diagnostic test variables by using the method of Doubilet and colleagues (77) and performed 10 000 simulations by randomly sampling values from these distributions. We then recorded the number of simulations in which the strategy under consideration was cost saving (more effective and less expensive than the alternative) or economically attractive (more effective and with an incremental cost < $100 000 per QALY gained). For description of the software used in our analysis, see the Appendix.

Role of the Funding Source

The funding source had no role in the design, conduct, or reporting of the study or in the decision to publish the manuscript.

Results

Because of the complexity of the analysis, we begin by summarizing our major findings. First, we found that the effectiveness and cost-effectiveness of management strategies depended critically on the pretest probability of malignancy and, to a lesser extent, the risk for surgical complications. Second, we found that CT was recommended as the initial test in nearly all circumstances, except when pretest probability was extremely high. Third, while nonselective use of FDG-PET was highly effective for pulmonary nodule diagnosis, we found that it was most cost-effective to use FDG-PET selectively, typically when pretest probability and CT results were discordant. Finally, we found that it was both highly effective and highly cost-effective to use surgery and needle biopsy aggressively once the results of imaging tests were known.

In patients with low pretest probability (26%), watchful waiting was the least effective and least expensive strategy (Table 1). A strategy that used CT but not FDG-PET was much more effective and cost less than $11 000 per QALY gained relative to watchful waiting. However, two strategies that used FDG-PET selectively were even more effective and cost less than $50 000 per QALY gained. In both of these strategies, CT was performed as the initial test and FDG-PET was used when CT results were possibly malignant. Surgery was recommended when the results of FDG-PET were positive, and needle biopsy was recommended when FDG-PET results were negative. Another strategy that used CT and FDG-PET nonselectively in all patients was most effective, but it cost almost $300 000 per QALY gained.

Table 1. Expected Costs, Quality-Adjusted Life-Years, and Incremental Cost-Effectiveness Ratios for Nondominated Strategies in Patients with Low, Intermediate, and High Pretest Probability of Malignancy

Table 1. Expected Costs, Quality-Adjusted Life-Years, and Incremental Cost-Effectiveness Ratios for Nondominated Strategies in Patients with Low, Intermediate, and High Pretest Probability of Malignancy

In patients with intermediate pretest probability (55%), watchful waiting was the least effective and least expensive approach (Table 1). Three strategies that used CT without FDG-PET cost less than $20 000 per QALY gained. In the most effective of these strategies, surgery was performed when CT results were possibly malignant and needle biopsy was performed when CT results were benign. Two strategies that included FDG-PET were more expensive and only marginally more effective than CT-based approaches and therefore cost more than $220 000 per QALY gained.

In patients with high pretest probability (79%), watchful waiting was again the least effective and least expensive approach (Table 1). A strategy that used CT but not FDG-PET was much more effective and cost less than $7000 per QALY gained relative to watchful waiting. Three strategies that used FDG-PET selectively were even more effective and cost less than $70 000 per QALY gained. In all three strategies, surgery was recommended when CT results were possibly malignant and FDG-PET was recommended when CT results were benign. The most effective of these strategies used surgery when FDG-PET results were positive and needle biopsy when FDG-PET results were negative.

Sensitivity Analysis

Figure 1 shows the importance of pretest probability in greater detail. Use of FDG-PET cost less than $100 000 per QALY gained when pretest probability was low (10% to 50%) and CT results were possibly malignant or when pretest probability was high (77% to 89%) and CT results were benign. Both of these situations resulted in intermediate post-test probabilities (20% to 69%). Surgery was favored at higher post-test probabilities ( 70%), biopsy was preferred at lower post-test probabilities (2% to 20%), and watchful waiting was preferred only at very low post-test probabilities (<2%). Surgery without any preliminary diagnostic testing was preferred when pretest probability was at least 90%. In patients at high risk for surgical complications, FDG-PET strategies cost less than $100 000 per QALY gained when post-test probability ranged between 35% and 84%.

Figure 1.

Recommended sequence of diagnostic testing in patients who are at average risk for surgical complications, according to pretest probability and the results of computed tomography (CT).topbottom

Several other variables affected the choice of strategy for patients with intermediate pretest probability, including the sensitivity (but not the specificity) of CT, the probability of nondiagnostic needle biopsy in patients with malignant nodules, and patient preferences for time spent under observation. Uncertainty exists about the sensitivity of CT, in part because there are no widely accepted CT criteria for determining whether a nodule is possibly malignant or benign. When we assumed that the true sensitivity of CT was less than 92.5% (compared with the base-case value of 96.5%), a strategy that used FDG-PET selectively cost less than $70 000 per QALY gained. In this strategy, FDG-PET was used when CT results were benign and surgery was recommended when CT results were possibly malignant.

There is also uncertainty about the diagnostic yield of needle biopsy (because this depends on operator experience) and patient preferences for time spent in observation. Selective use of FDG-PET (when CT results were benign) cost less than $25 000 per QALY gained when we assumed that the probability of nondiagnostic needle biopsy in patients with malignant nodules was 19% (base-case value of 8%), or when the relative utility of the time spent in observation was assumed to be 0.97 or less (base-case value of 1.00). A relative utility of 0.97 implies that an individual would accept a 3% risk for instant death in order to know whether the nodule was malignant or benign.

The choice of strategy was not affected by varying other model parameters within the ranges tested, including the discount rate, the diagnostic accuracy of FDG-PET, or the cost of diagnostic tests (including FDG-PET). Similarly, the choice of strategy was not affected when we assumed that FDG-PET was 25% less sensitive and 16% more specific when CT results were benign, as has been observed in studies of FDG-PET and CT for mediastinal staging in patients with nonsmall-cell lung cancer (78).

Probabilistic sensitivity analysis showed that in patients with low and high pretest probability, FDG-PET strategies were cost saving or cost less than $100 000 per QALY gained in 76.7% and 99.9% of all simulations, respectively. For patients with intermediate pretest probability, FDG-PET strategies were cost saving or economically attractive in fewer than 25% of all simulations.

Clinical Recommendations

Figure 2 outlines a clinical algorithm for managing patients with new, noncalcified pulmonary nodules that is based on our results. In patients with low pretest probability (10% to 50%), FDG-PET should be used selectively when CT results are possibly malignant. When FDG-PET results are positive, surgery is both highly cost-effective and slightly more effective than needle biopsy. When FDG-PET results are negative, needle biopsy is more effective than observation. This is because, although uncommon, false-negative results of FDG-PET have potentially serious consequences (such as delayed diagnosis and missed opportunities for curative surgery). When CT results are benign, observation or needle biopsy should be used. Our analysis suggests that the latter approach is slightly more effective.

Figure 2.

Suggested algorithm for clinical management of patients with solitary pulmonary nodules who are at average risk for surgical complications.CT

For patients with intermediate pretest probability (51% to 76%), we recommend surgery or needle biopsy when CT results are possibly malignant and needle biopsy or observation when CT results are benign (Figure 2). More aggressive use of surgery and needle biopsy results in slightly better health outcomes and slightly higher costs. The choice between more or less aggressive approaches should depend on factors such as the risk for surgical complications, the expected yield of needle biopsy, and patient preferences. For example, in patients who have severe comorbid conditions that increase the risk of surgery, it may be preferable to establish a malignant diagnosis with needle biopsy before sending the patient to surgery.

For patients with high pretest probability (77% to 90%), we recommend surgery when CT results are possibly malignant, unless the patient is at very high risk for operative complications (Figure 2). Patients should undergo FDG-PET when CT results are benign. When FDG-PET results are positive, surgery should be performed. When FDG-PET results are negative, needle biopsy is marginally more effective than watchful waiting, although some clinicians might prefer observation in this situation.

Discussion

Pulmonary nodule diagnosis is challenging because the clinician and patient must consider many factors when discussing management options, including the risks and benefits of several possible diagnostic tests, patient preferences for invasive and noninvasive procedures, and the uncertain consequences of delayed diagnosis when watchful waiting is used as a management strategy. In this analysis, we used quantitative methods to synthesize these and other factors.

Pulmonary nodule diagnosis should always begin with a careful review of the chest radiograph and comparison with previous radiographs. Most experts agree that if a central, laminated, diffuse, or popcorn pattern of calcification is seen, a benign diagnosis is likely and observation with serial radiographs is appropriate (1, 79). Likewise, because doubling times for malignant nodules rarely exceed 700 days, 2-year radiographic stability strongly implies a benign cause. In the absence of benign calcification or documented radiographic stability, the clinician should estimate the pretest probability of malignancy. Once these steps have been taken, our findings can be used to guide subsequent management.

We confirmed that CT should be the initial test in the management of nearly all patients with pulmonary nodules. Computed tomography is inexpensive and noninvasive and may be highly specific for identifying some benign nodules. In contrast, FDG-PET as the initial test is never economically attractive. We also found that the choice of subsequent tests depends most critically on the pretest probability of malignancy and the risk for surgical complications. Other potentially important factors include the sensitivity of CT, the probability of nondiagnostic needle biopsy, and patient preferences for time spent in watchful waiting.

Although FDG-PET strategies were highly effective over a wide range of pretest probabilities, these strategies were not necessarily cost-effective. Our results indicate that FDG-PET should be used selectively when pretest probability and CT results are discordant; in these cases, post-test probability will be intermediate. Selective use of FDG-PET limits costs by reducing the total number of FDG-PET studies performed and ensures that FDG-PET is used when the diagnosis is most in doubt. Table 2 summarizes specific recommendations on when to use CT, FDG-PET, watchful waiting, needle biopsy, and surgery.

Table 2. Recommendations on the Use of Computed Tomography, Positron Emission Tomography with 18-Fluorodeoxyglucose, Watchful Waiting, Transthoracic Needle Biopsy, and Surgery

Our results support and extend the findings of other studies. In a decision analysis that did not consider costs, Cummings and colleagues (9) found that the choice of strategy depended on the pretest probability of malignancy. Watchful waiting was preferred over biopsy when the probability of cancer was less than 3%, and surgery was preferred over biopsy when the probability of cancer was greater than 68%. Our threshold values for watchful waiting and surgery were very similar to theirs, despite the fact that they made less pessimistic assumptions about the consequences of delayed diagnosis in patients with malignant nodules who were managed by observation. We extend their work by demonstrating that FDG-PET replaces needle biopsy when the post-test probability of malignancy ranges from 20% to 69%. In a recent cost-effectiveness analysis based on reimbursement rates in Germany, Dietlein and colleagues (80) reported that their threshold for performing surgery instead of FDG-PET occurred at a similar probability of 75%. In another cost-effectiveness analysis, results for patients with low pretest probability were similar to ours, although we recommend strategies in patients with intermediate and high pretest probability that these authors did not consider (81).

Our analysis has several limitations. First, the natural history of untreated malignant pulmonary nodules is not known. We modeled the consequences of delayed diagnosis when watchful waiting was used in patients with malignant nodules. Few empirical data exist to validate our model. However, our results were very similar when we adopted Cummings and colleagues' less pessimistic assumptions about the consequences of delayed diagnosis.

Second, our base-case analysis assumed that test performance was conditionally independent, or that the sensitivity and specificity of FDG-PET did not differ depending on the results of CT. Although FDG-PET and CT identify malignant nodules by different mechanisms, their results might be correlated. For example, our group and others have observed that, when used for mediastinal staging in patients with nonsmall-cell lung cancer, FDG-PET is less sensitive and more specific when CT findings are negative (78, 82). We are not aware of any data on the conditional performance of these tests for pulmonary nodule diagnosis. In fact, most studies of FDG-PET limited enrollment to participants with possibly malignant findings on CT. Thus, our base-case estimates of sensitivity and specificity for FDG-PET best reflect its performance when CT results are possibly malignant, and concerns about conditional test performance do not compromise our recommendation to use FDG-PET selectively when pretest probability is low and CT results are possibly malignant. Still, if FDG-PET is less sensitive and more specific than our base-case estimates when CT results are benign, this could raise doubts about our recommendation to use FDG-PET when pretest probability is high. However, sensitivity analysis showed that our results did not change when we assumed that the sensitivity of FDG-PET was as low as 50% in patients with benign results on CT. Improving the specificity of FDG-PET would only strengthen the recommendation to use it in this setting.

Our analysis did not consider several other potential benefits of FDG-PET imaging. Use of FDG-PET is more accurate than CT for detecting regional lymph node metastases (82, 83), which occur in approximately 12% of patients with T1 lung cancer (12-19), and may also detect occult distant metastases (82). Finally, future advances in FDG-PET technology may improve accuracy or reduce costs. Several groups have recently described an FDG imaging technique that does not require a dedicated PET scanner but rather performs coincidence imaging by using a modified dual-detector camera (84-87). While this technique is less expensive than FDG imaging with a dedicated PET scanner, its diagnostic accuracy has not been evaluated in large, well-designed studies.

We conclude that patients with new, noncalcified pulmonary nodules should first be classified according to pretest probability and the risk for surgical complications, after which CT should be performed. For patients who are at average risk for surgical complications, FDG-PET should be used selectively when pretest probability and CT results are discordant. For patients at high risk for surgical complications with low or intermediate pretest probability, FDG-PET should be used when CT results are possibly malignant. In most other circumstances, CT-based strategies result in similar quality-adjusted life expectancy and lower costs.

Appendix

In this appendix, we describe in greater detail the methods and results of our analysis of alternative management strategies for patients with solitary pulmonary nodules. Readers should consult the print version of the manuscript for background information, results of the base-case analysis, results of one-way sensitivity analysis, and a discussion of the results. We focus on describing the assumptions of the Markov model that we used to estimate long-term costs and outcomes for patients with malignant pulmonary nodules. In addition, we provide detailed information regarding studies of diagnostic test performance and a critique of their methods, as well as more information regarding our sources of data for cost and utility estimates. Finally, we present selected results that did not appear in the print version of the manuscript because of space limitations, including complete results of probabilistic sensitivity analysis.

Methods

The target population for this analysis was all adult patients found to have a new, noncalcified solitary pulmonary nodule on chest radiograph and no known extra-thoracic malignancy. We assumed that there was no absolute contraindication to invasive biopsy or surgery, because patients with such contraindications would not be likely to undergo aggressive diagnostic evaluation.

Decision Model Structure and Assumptions

Appendix Figures 1 and 2 illustrate the structure of the decision model. The model compared 40 clinically plausible sequences of five diagnostic interventions: CT, FDG-PET, transthoracic needle biopsy, surgery, and watchful waiting. Appendix Table 2 is a complete list of strategies. We evaluated all plausible sequences of diagnostic tests to compare strategies with the next most effective alternative when making cost-effectiveness comparisons. Comparing an intervention with a suboptimal alternative may result in overestimating the intervention's true cost-effectiveness (10). In addition, strategies that might seem to be counterintuitive often prove to be highly cost-effective under certain conditions.

Appendix (Figure 1).

Decision model.ACTFDG-PETBCD

Appendix (Figure 2).

Decision model subtrees.

Appendix Table 2. Alternative Strategies for Management of Patients with Solitary Pulmonary Nodules

The order of possible test sequences was unconstrained, with two exceptions. First, CT and FDG-PET were never performed after needle biopsy or surgery, because performing an imaging test after an invasive diagnostic procedure would be unusual. Similarly, needle biopsy and observation were never performed after surgery. Computed tomography, FDG-PET, needle biopsy, surgery, or watchful waiting could be selected as the initial diagnostic intervention (Appendix Figure 1).

We assumed that most biopsies were performed under CT guidance, but fluoroscopic guidance was used in test sequences that did not include CT. We considered needle biopsy to be nondiagnostic unless a specific benign or malignant diagnosis was obtained. We assumed that surgery would be performed if the biopsy revealed malignancy. If the biopsy revealed a specific benign diagnosis, we assumed that the patient would be managed accordingly. After a nondiagnostic needle biopsy, either surgery or watchful waiting could be selected as the next diagnostic intervention (Appendix Figure 2).

A final diagnosis was established at the time of surgery or, alternatively, after 24 months of observation. In the observation (watchful waiting) strategy, serial chest radiographs were obtained at 1, 2, 4, and 6 months, and every 3 months thereafter. We assumed that surgery would be performed if nodule growth was detected at any time. If no growth was observed after 24 months, we assumed that the nodule was benign. It is important to note that the optimal timing of serial radiographs has not been determined. However, in our protocol, imaging was used more frequently than the protocol recommended by the Early Lung Cancer Action Project (ELCAP) investigators, who recommended that CT be performed at 3, 6, 12, and 24 months after identification of nodules that measured less than 1 cm in diameter (88). Furthermore, we assumed that chest radiography had a sensitivity of 100% for detecting growth, defined as one doubling in tumor volume or a change in nodule size from 2 cm to 2.5 cm in diameter. We believe that by making this assumption, the modeled performance of chest radiography compares favorably with the actual performance of CT in everyday practice. In addition, we suspect that chest radiography is more widely used than CT in practice settings for watchful waiting in patients with nodules that measure 2 cm in diameter. However, because of the better spatial resolution of CT and the difficulty in detecting growth in small pulmonary nodules, we believe that CT should be used for watchful waiting in patients with nodules that measure less than 1 cm to 1.5 cm in diameter.

Modeling Long-Term Costs and Clinical Outcomes

We developed a state-transition (Markov) model to estimate long-term outcomes and costs for patients with malignant and benign pulmonary nodules (Appendix Figure 3). The model followed individual patients in the hypothetical study cohort over their remaining life span. Individuals were assumed to make transitions from one health state to another over time. Before the time of diagnosis, all patients were considered to be in the unknown health state, reflecting the unknown nature of the diagnosis. Within this state, patients with malignant nodules who were managed by watchful waiting were at risk for disease progression from local to regional disease and from regional to distant disease during the observation period. At the time of diagnosis, patients were assumed to transition from the unknown state to one of three other health states (benign, local, or regional), depending on the diagnosis and stage of disease. We assumed that all patients with malignant nodules eventually underwent surgery, although surgery was inevitably delayed in patients whose management strategy included watchful waiting. After surgery, all patients with local-stage malignant disease were at risk for recurrence. Similarly, patients with regional-stage disease were at risk for disease progression. Patients who remained in the local and regional health states for 5 years after the time of diagnosis were considered to be free of cancer (89). After this time, we assumed that life expectancy was normal for age. We assumed that all patients with distant-stage lung cancer eventually died of their cancer, if they did not die first of some other cause.

Appendix (Figure 3).

Markov model.

Determining Markov Model Transition Probabilities

To estimate the monthly probability of cancer recurrence for patients with malignant pulmonary nodules, we constructed survival curves for 1207 Medicare beneficiaries with surgically treated, local-stage, malignant pulmonary nodules (T1N0M0) from the SEER tumor registry for 1990 to 1993 (11). We assumed that some patients would have recurrent disease and then die of cancer and that the remainder would eventually die of other causes. We estimated the monthly probability of death from recurrent lung cancer by using SEER tumor registry data for 10 835 Medicare beneficiaries with distant-stage disease. We determined the monthly probability of death from other causes by using age-specific values from 1996 U.S. life tables (90). We assumed that the probability of recurrence decreased gradually over time. We then identified monthly probabilities of recurrence that produced a modeled survival curve that most closely approximated observed survival in the SEER cohort. We fit this curve by minimizing the sum of the squared differences between points representing the probability of survival at years 1 through 5. Appendix Figure 4 shows the survival curve for the observed cohort and modeled survival when probabilities of recurrence were set at our base-case values (Appendix Table 1).

Appendix (Figure 4).

Observed and modeled survival for patients with local, regional, and distant lung cancer.SEER

We used an identical procedure to estimate the monthly probability of progression from regional to distant-stage lung cancer. We approximated a survival curve for a cohort that included 1954 Medicare enrollees with pathologically confirmed, regional-stage lung cancer (any T N13 M0) from the SEER registry. Appendix Figure 4 shows observed and modeled survival when probabilities of progression from regional to distant disease were set at our base-case values (Appendix Table 1).

Determining the Probability of Disease Progression during Watchful Waiting

We used similar methods to model the monthly probability of disease progression during watchful waiting. We assumed that monthly probabilities for disease progression depended on the doubling time of the nodule, a measure of the tumor growth rate. We used data from the Veterans AdministrationArmed Forces Cooperative Study on Asymptomatic Pulmonary Nodules to estimate the distribution of doubling times for malignant nodules (20). The mean doubling time was 5.24 months (median, 4 months).

To predict life expectancy for patients with malignant nodules with different doubling times, we adopted a simple model of the natural history of lung cancer (91-93). The model assumes that a tumor starts as a single cell that measures 10µmin diameter and doubles in volume at a constant rate. Under these assumptions, a nodule that measures 2 cm in diameter has doubled in volume 33 times. It is further assumed that death occurs, on average, after 40 tumor doublings when the diameter of the tumor measures 10 cm. The model predicts that in the absence of treatment, life expectancy is 36.7 months for a patient with a 2-cm nodule that doubles in volume every 5.24 months. Because empirical data on the natural history of untreated malignant nodules are lacking, we validated this prediction by surveying a group of academic clinicians for their expert opinion. We asked a convenience sample of 21 internists, pulmonary specialists, and thoracic surgeons to estimate the life expectancy of an otherwise healthy, 62-year-old man with a 2-cm malignant pulmonary nodule who declined treatment, assuming that the growth rate of the nodule was average. Estimated mean life expectancy (SD) was 35.12 16.33 months (median, 32 months), which closely agreed with what the model predicted (Gould MK. Unpublished data).

We used the declining exponential approximation of life expectancy (DEALE) to construct survival curves for patients who had nodules with different doubling times (94, 95). The DEALE assumes that survival is approximated by a simple declining exponential function. Under the assumptions of the DEALE, life expectancy is the reciprocal of the average compound mortality rate. A life expectancy of 36.7 months corresponds to a constant mortality rate of 0.327 per year. Predicted survival (S) at time (t) is given by the formula: S = e^rt, where r is the mortality rate, and t is measured in years. For example, when r = 0.327, the 1-year survival rate is 72.1%, and the 5-year survival rate is 19.5%.

To determine the monthly probability of disease progression, we assumed that untreated lung cancer progresses sequentially from local to regional to distant disease and then to death. We assumed that the transition probabilities for local to regional disease and regional to distant disease were equal. We determined the monthly probability of death from distant lung cancer and the probability of death from other causes by using data from the SEER tumor registry and U.S. life tables, respectively. We then identified transition probabilities that produced survival curves that most closely approximated the curves that we obtained by using the natural history model and the assumptions of the DEALE. To fit these curves, we minimized the sum of the squared differences between points representing the probability of survival at years 1 through 5. In the case of a malignant nodule with a doubling time of 5.24 months, we calculated that the monthly probability of progression from local to regional disease during the observation period was 8.4%. Appendix Figure 5 shows the distribution of doubling times for malignant pulmonary nodules and the corresponding transition probabilities that we derived.

Appendix (Figure 5).

Distribution of tumor doubling times and corresponding probabilities of disease progression during the observation period.black circles

Other investigators have used a different approach to estimate the negative consequences of delayed diagnosis in patients with malignant nodules who were managed by observation. Cummings and colleagues (9) observed that there was a linear relationship between tumor size and survival after resection of malignant lung tumors. The relationship that they observed was described by the equation r = (0.039 d)0.0145, where r is the disease-specific mortality rate (which is assumed to be constant over time) and d is the diameter of the nodule in centimeters. Like us, they assumed that growth would be detected when the nodule doubled once in volume (for example, in a patient with a nodule that measured 2 cm in diameter, growth would be detected when the nodule measured 2.5 cm in diameter). Under these assumptions, they estimated that 5-year survival would be reduced by 5% in patients who were managed by observation at some point in their evaluation. Using the same set of assumptions, Gambhir and colleagues (81) calculated that life expectancy for a 64-year-old man with a 2.5-cm nodule would be reduced by 14%, from 6.62 years to 5.67 years, if diagnosis and treatment were delayed by one doubling time. The main limitation of these previous analyses is that the linear relationship between tumor size and survival was derived from studies in which the definition of pulmonary nodules included lesions that measured up to 6 cm in diameter (96, 97). In one of the studies, almost 40% of patients had pulmonary masses 3.5 cm to 6 cm in diameter (98). Recent evidence suggests that nodule diameter may not predict survival within the subgroup of patients with malignant nodules that measure no more than 3 cm in diameter, who are the focus of our analysis (99).

Data and Assumptions

We derived estimates for patient and nodule characteristics, diagnostic testing variables, costs, and utilities from clinical and administrative data sources (Appendix Table 1). Estimates of the diagnostic accuracy of FDG-PET imaging were obtained from a published meta-analysis, whose methods and results are summarized below (22). A single reviewer evaluated most studies of CT, needle biopsy, and surgery. For these tests, we used a descriptive approach to highlight aspects of study quality.

Patient and Nodule Characteristics. Our base-case analysis considered a hypothetical cohort of 62-year-old men and women because in eight recent studies of FDG-PET for pulmonary nodule diagnosis, roughly 60% of the participants were men and the mean age was 61.8 years (25-28, 30, 31, 33, 35). The base-case analysis assumed that the pulmonary nodule measured 2 cm in diameter. We assumed that 12.5% of patients with malignant nodules would have regional lymph node involvement, based on the median prevalence of mediastinal metastases in eight studies of CT for mediastinal staging in patients with stage T1 bronchogenic carcinoma (12-19). The monthly probability that a benign nodule would grow in the first month was 28%, based on the median proportion of benign nodules that were caused by an acute or subacute inflammatory process in 10 recent studies of FDG-PET for pulmonary nodule diagnosis (23, 25-28, 30, 32-35). Because most benign nodules grow rapidly or not at all, the monthly probability that a benign nodule would grow in subsequent months was assumed to be 0.5%.

Diagnostic Test Performance: FDG-PET. To determine the diagnostic accuracy of FDG-PET, we performed a meta-analysis. Although our methods and results have been published elsewhere (22), we summarize them below. Our computerized search strategy is outlined in Appendix Table 3. We identified 13 studies of FDG-PET that enrolled 450 patients with pulmonary nodules (23-35). The number of participants ranged between 19 and 100, and the mean age of participants ranged between 58 and 71 years (Appendix Table 4). The median prevalence of malignancy was 65.8% (range, 46% to 79%). Six studies limited enrollment to participants with pulmonary nodules (25, 30-32, 34, 35). Seven other studies enrolled more heterogeneous groups of patients with pulmonary nodules and larger mass lesions but provided separate results for participants with pulmonary nodules (23, 24, 26-29, 33). We only used data from participants with pulmonary nodules to perform quantitative analyses.

Appendix Table 3. MEDLINE Search for Studies of Positron Emission Tomography with 18-Fluorodeoxyglucose

Appendix Table 4. Studies of Positron Emission Tomography with 18-Fluorodeoxyglucose for Pulmonary Nodule Diagnosis

To identify high-quality studies, we adapted criteria for methodologic quality proposed by Kent and colleagues (100), who evaluated imaging tests to diagnose lumbar spinal stenosis. These criteria have also been used to assess the quality of studies of polymerase chain reaction to diagnose HIV infection (37, 101). The revised criteria cover seven dimensions: technical quality of the index test, technical quality of the reference test, independence of test interpretation, description of the study sample, cohort assembly, sample size, and unit of data analysis. Eleven of 13 studies satisfied at least 70% of our study quality criteria (24-33, 35). The other two studies satisfied between 50% and 69% of our criteria (23, 34). Most studies met our criteria for the technical quality of FDG-PET, although three studies administered doses of FDG that were lower than recommended (34, 35, 102), and three studies did not specify whether participants were examined in the fasting state (23, 25, 27). All studies but one adequately described reference tests that were used to confirm the presence of malignancy or to establish a benign diagnosis (23). Three studies did not report whether FDG-PET readers were blinded to the results of the reference test (23, 30, 34), and several studies did not indicate whether FDG-PET readers were blinded to the clinical characteristics of the participants and other radiographic data. All studies prospectively enrolled a relevant cohort of participants, and all but two studies indicated that the individual patient was the unit of the analysis (27, 35).

To quantitatively summarize study results, we used a meta-analytic method to construct a summary ROC curve for FDG-PET (36, 37). The ROC curves illustrate the tradeoff between sensitivity and specificity as the threshold for defining a positive test result varies from most stringent to least stringent. Our meta-analytic method rests on the assumption that individual study estimates of sensitivity and specificity represent unique points on a common ROC curve.

For each study, we constructed 2 2 contingency tables in which all participants were classified as being FDG-PETpositive ornegative and as having a malignant or benign pulmonary nodule. We calculated the true-positive rate (TPR = sensitivity), the false-positive rate (FPR = 1specificity) and the log odds ratio (log odds TPRlog odds FPR). The log odds ratio is a measure of diagnostic test performance that accounts for the fact that the TPR and FPR are positively correlated. Next, we logistically transformed the TPR and FPR and fit a summary ROC curve with linear regression, by using the log odds ratio as the dependent variable and an implied function of the test threshold (log odds TPR + log odds FPR) as the independent variable (36).

A limitation of this method is that the transformation requires the use of a correction factor when the 2 2 table for a study contains one or more zero values (that is, when reported sensitivity or specificity are perfect). An advantage of the method is that it provides a statistical test of the hypothesis that the variance in the group with malignant disease and the variance in the group without malignant disease are equal. The variances are not equal when the slope of the regression line is significantly different from zero. When the slope is not significantly different from zero, the resulting ROC curve is symmetrical and can be described by a common or summary log odds ratio. When this condition was met, we used the MantelHaenszel method for pooling odds ratios because this method does not require a correction factor (103). The two methods produced nearly identical results. Estimates of uncertainty were derived by using the MantelHaenszel method and were expressed in terms of 95% CIs.

In the 13 studies, the mean sensitivity and specificity were 93.9% and 85.8%, and the median sensitivity and specificity were 98.0% (interquartile range, 90% to 100%) and 83.3% (interquartile range, 80% to 100%). Appendix Figure 6 displays the summary ROC curve for FDG-PET. For our base-case estimates, we selected an operating point on the ROC curve that corresponded to the median specificity of FDG-PET in the 13 studies. We used the median specificity because we wanted to estimate where FDG-PET operates in current practice. Other approaches are possible, but not necessarily better. At this point on the ROC curve, sensitivity and specificity were 94.2% (95% CI, 89.1% to 97.0%) and 83.3%, respectively (22).

Appendix (Figure 6).

Summary receiver-operating characteristic (ROC) curve for positron emission tomography with 18-fluorodeoxyglucose (FDG-PET).dotted linesblack squareblack circle

Diagnostic Test Performance: CT. To determine the diagnostic accuracy of CT, we searched MEDLINE for English-language studies published before January 2000 by combining the MeSH term tomography, X-ray computed with a list of MeSH terms and keywords for lung cancer and pulmonary nodules. In addition, we scanned the reference lists of retrieved studies and review articles. We updated this literature search in November 2001. We identified 18 studies of CT for the diagnosis of focal pulmonary lesions (Appendix Tables 5, 6, and 7) (2-4, 38-47, 104-108). Interpreting the literature on CT is challenging because several different techniques have been described, including noncontrast CT, CT densitometry, high-resolution CT, and CT with nodule enhancement. In addition, many of the studies were performed more than 10 to 20 years ago.

Appendix Table 5. Studies of Computed Tomography Densitometry for Diagnosis of Pulmonary Nodules and Mass Lesions

Appendix Table 6. Studies of High-Resolution Computed Tomography for Pulmonary Nodule Diagnosis

Appendix Table 7. Studies of Dynamic Computed Tomography with Nodule Enhancement

We identified nine studies that evaluated noncontrast CT or CT densitometry (4, 38-45), two studies that evaluated high-resolution CT (46, 47), and one study that evaluated both CT densitometry and high-resolution CT (2) (Appendix Tables 5 and 6). Computed tomography densitometry attempts to identify benign nodules on the basis of increased density characteristics that suggest occult calcification. In past years, a reference phantom was used to account for inter- and intrascanner differences in measuring nodule density, but this is no longer used in clinical practice. More recent studies of thin-section (high-resolution) CT have used different criteria to distinguish benign from malignant nodules (Appendix Table 6). One study used a set of criteria that proved to be sensitive but not specific for identifying malignancy (47), while another study used criteria that were more specific and less sensitive (46).

Studies of noncontrast CT and high-resolution CT enrolled between 35 and 720 participants, and most pulmonary lesions measured 3 cm or less in diameter (Appendix Tables 5 and 6). The prevalence of malignancy varied greatly, ranging between 15% and 78%. All but two studies reported the technical characteristics of the CT examinations in detail (43, 45). However, only three studies reported prospective enrollment of participants (2, 45, 47), and only one study reported that CT readers were blinded to the final diagnosis (47). In the other studies, these aspects of study design were not mentioned. All studies used acceptable reference tests to confirm a diagnosis of malignancy. Most studies required at least 18 months of clinical and radiographic follow-up for confirmation of benign disease without histologic proof, but four studies permitted shorter follow-up periods (38-40, 45).

Several studies have examined functional or dynamic imaging with CT (3, 104-108). In these studies, dynamic enhancement of lung nodules with iodinated contrast material is thought to identify increased vascularity that is strongly associated with malignancy (Appendix Table 7). In a recent multicenter study involving 356 participants, Swensen and colleagues (108) found that absence of enhancement strongly predicted a benign cause. The sensitivity and specificity of dynamic CT for identifying malignancy were 98% and 58%, respectively. Although this test is extremely promising, it is not widely used outside of research settings. In addition, it is used only when the nodule is radiographically indeterminate (for example, when thin-section CT shows no evidence of calcification). We chose to derive estimates for the sensitivity and specificity of CT from studies of CT densitometry and high-resolution CT, despite their limitations, because we aimed to examine the incremental benefits and costs of adding FDG-PET imaging to diagnostic strategies in current use. However, we also examined the potential role of dynamic CT with nodule enhancement in a sensitivity analysis.

In 12 studies of noncontrast CT and high-resolution CT, the mean sensitivity and specificity were 92.5% and 53.6% and the median sensitivity and specificity were 99.2% (interquartile range, 91% to 100%) and 55.8% (interquartile range, 45% to 60%). To derive base-case estimates of sensitivity and specificity, we used the same meta-analytic method that we used for studies of FDG-PET to construct a summary ROC curve for CT (Appendix Figure 7). Because the variance in the group with malignant disease and the variance in the group with benign disease were not equal, we used the method of Moses and colleagues (36) to obtain our base-case values and estimates of uncertainty. For our base-case estimates, we selected an operating point on the ROC curve that corresponded to the median specificity in the studies. At this point on the ROC curve, the sensitivity and specificity for identifying malignant nodules were 96.5% (CI, 80.9% to 99.5%) and 55.8%, respectively. We obtained similar results when we restricted our analysis to more recent studies of high-resolution CT. In this analysis, sensitivity and specificity were 96.5% (CI, 82.9% to 99.4%) and 58.5%, respectively.

Appendix (Figure 7).

Summary receiver-operating characteristic (ROC) curve for computed tomography (CT).dotted lines

In the radiology literature, the term indeterminate designates a positive CT result and the term benign designates a negative CT result. Because indeterminate is a potentially confusing term, we use the phrase possibly malignant to describe indeterminate, or positive, results. Benign nodules typically have smooth borders and diffusely increased density, suggesting the presence of calcification. It is important to note that this definition implies that most pulmonary nodules will be indeterminate (or possibly malignant) by CT criteria.

Conditional Performance of FDG-PET and CT. In the base-case analysis, we assumed that the results of FDG-PET and CT were independent, or that the sensitivity and specificity of FDG-PET were the same regardless of the results of CT. This implies that the test results are not correlated. This is plausible because CT and FDG-PET characterize nodules by distinct mechanisms: FDG-PET identifies malignant nodules on the basis of increased glucose uptake and metabolism, while CT sometimes identifies benign lesions on the basis of density characteristics that suggest calcification. However, in previous work that examined imaging tests for mediastinal lymph node staging in patients with nonsmall-cell lung cancer, we found that the sensitivity and specificity of FDG-PET for identifying mediastinal metastases depended on the results of CT (78). More specifically, FDG-PET was 25% less sensitive and 16% more specific when CT revealed no lymph node enlargement relative to when CT detected enlarged nodes. Nevertheless, this relationship may not hold true for pulmonary nodule diagnosis because CT identifies lymph node metastases based on size criteria, rather than by density characteristics, as is true for pulmonary nodules.

Although data on the conditional performance of FDG-PET and CT for mediastinal staging have been published, we could not identify any studies that examined the conditional performance of FDG-PET and CT to diagnose pulmonary nodules. In fact, most studies of FDG-PET for pulmonary nodule diagnosis excluded participants with nodules that appeared benign on CT and limited enrollment to participants with CT findings that were possibly malignant. Thus, our base-case estimates of sensitivity and specificity apply directly when CT results are indeterminate and less well when CT results are benign. However, to explore the potential importance of the independent test assumption, we performed a sensitivity analysis in which we assumed that the conditional performance of FDG-PET and CT for pulmonary nodule diagnosis was similar to their conditional performance for mediastinal staging. We tested even more extreme values of the sensitivity and specificity of FDG-PET when CT results were benign.

Diagnostic Test Performance: Needle Biopsy. To determine the diagnostic accuracy of CT-guided needle biopsy and the risk for biopsy-related complications, we searched MEDLINE for English-language studies published before January 2000 by combining the MeSH term biopsy, needle with a list of MeSH terms and keywords for lung cancer and pulmonary nodules. We also scanned the reference lists of retrieved studies and review articles. We updated this literature search in November 2001. We included studies that limited enrollment to participants with pulmonary nodules that measured no more than 4 cm in diameter, as well as studies that reported results separately for participants with pulmonary nodules. We excluded studies that used means other than CT guidance for localizing nodules in more than 10% of participants. We identified nine studies that met these criteria (27, 48-55) (Appendix Table 8). Another study was excluded because we strongly suspected that it presented previously reported data (109).

Appendix Table 8. Studies of Computed TomographyGuided Needle Biopsy for Pulmonary Nodule Diagnosis

The studies enrolled between 22 and 220 participants with pulmonary nodules. Two studies included patients with pulmonary nodules that measured up to 4 cm in diameter (48, 49), while the remaining studies reported results for patients with nodules that measured less than 1.5 to 3 cm in diameter. The prevalence of malignancy was very high, ranging from 62% to 85%. All studies except one described in detail the technical aspects of how needle biopsies were performed (27). There was little heterogeneity across studies regarding biopsy methods. Specimens were obtained for cytologic examination in all of the studies, but core biopsies were also performed in two studies (54, 55). In four studies, benign diagnoses that were not verified by surgery or autopsy were confirmed by clinical follow-up of at least 15 to 24 months, and malignant diagnoses were established by surgery, autopsy, or, in the case of nodules due to metastasis, cytologic characteristics that were similar to those of the primary tumor (50-52, 55). The remaining studies described less optimal reference standards. Three studies reported that consecutive patients were enrolled prospectively (51, 54, 55). In one study, 105 eligible patients were excluded from the analysis because the final diagnosis could not be established (50). None of the studies mentioned whether the pathologist who was responsible for interpreting the biopsy results was blinded to the final diagnosis. We used data from all nine studies to obtain base-case estimates of diagnostic accuracy and the risk for complications because results across studies were remarkably consistent (Appendix Table 8). Results of studies that used optimal reference tests were not significantly different from results of studies that used less optimal reference standards (P > 0.2).

We collected data on the percentage of biopsies that were diagnostic or nondiagnostic. Diagnostic biopsies were defined as those that yielded a specific malignant or benign diagnosis. Nondiagnostic biopsies included biopsy results that were atypical or suspicious for malignancy, as well as those that were described as nonspecific benign. The median percentage of diagnostic biopsies in the nine studies was 80% (interquartile range, 75% to 87%). The median percentage of diagnostic biopsies in nodules that proved to be malignant was 92% (interquartile range, 81% to 94%), and the median percentage of diagnostic biopsies in nodules that proved to be benign was 56% (interquartile range, 47% to 77%). Thus, nondiagnostic biopsies provided some diagnostic information because nondiagnostic results were much more likely to occur in benign lesions.

Because we thought it was important to account for nondiagnostic biopsies in our analysis, we modeled the diagnostic accuracy of transthoracic needle biopsy in two steps. The initial step determined whether the biopsy was diagnostic or nondiagnostic. If the biopsy was nondiagnostic, the model calculated the post-test probability that the nodule was benign or malignant, based on the conditional probability of these diagnoses after a nondiagnostic biopsy. If the biopsy yielded a specific benign or malignant diagnosis, a second step determined whether that diagnosis was correct (true-positive or true-negative) or not (false-positive or false-negative). Thus, estimates of sensitivity and specificity for needle biopsy were conditioned on obtaining a specific benign or malignant diagnosis.

We used the same meta-analytic method that we used for studies of FDG-PET to construct a summary ROC curve for CT-guided needle biopsy when a specific benign or malignant diagnosis was revealed. Because this ROC curve was symmetrical, we used the MantelHaenszel method to obtain base-case values and estimates of uncertainty. For our base-case estimates, we selected an operating point on the ROC curve that corresponded to the mean sensitivity of needle biopsy in the nine studies. At this point on the ROC curve, sensitivity and specificity were 96.3% (CI, 82.4% to 99.3%) and 98%, respectively. We used the mean sensitivity because the median sensitivity and specificity were 100%, which would have implied that specificity (or sensitivity) was 0%.

Our literature search yielded three studies of needle biopsy performed under fluoroscope guidance in which enrollment was limited to participants with pulmonary nodules (56-58). In one study with a very high prevalence of malignancy (80%), the diagnostic yield of fluoroscope-guided needle biopsy was 84% for nodules that measured 2 to 4 cm in diameter (56). However, in two other studies with a lower prevalence of malignancy, the diagnostic yield was only 36% to 43% (57, 58). We assumed that the diagnostic yield of fluoroscope-guided needle biopsy was 10% lower than the yield of CT-guided biopsy, but that sensitivity and specificity were the same as for CT-guided biopsy, provided that the biopsy yielded a specific benign or malignant diagnosis.

The most important potential complication of transthoracic needle biopsy is pneumothorax. In the nine studies of CT-guided biopsy, the median prevalence of minor pneumothorax was 24% (interquartile range, 20% to 35%) and the median prevalence of major pneumothorax requiring chest tube drainage was 5% (interquartile range, 4% to 11%). We assumed that the probability of death from needle biopsy was 0.05% because no deaths were reported in more than 750 reported procedures.

Diagnostic Test Performance: Surgery. Because excisional biopsy is the gold standard for determining whether a lung nodule is benign or malignant, we assumed that video-assisted thoracoscopic surgery (VATS) was 100% sensitive and specific for pulmonary nodule diagnosis. This implies that our analysis is limited to patients with peripheral nodules that are amenable to VATS. We assumed that VATS would be converted to a full thoracotomy with lobectomy for resection of malignant nodules, as is standard practice in most centers.

To estimate the rates of fatal and nonfatal complications for surgical procedures, we searched MEDLINE for English-language studies published before January 2000 by combining the MeSH headings thoracotomy and thoracoscopy with a list of MeSH terms and keywords for pulmonary nodules and lung cancer. We identified 18 studies of VATS. We excluded 10 studies that described major lung resections (usually lobectomy) that were performed through VATS, because this procedure is performed only in specialized centers by highly experienced thoracic surgeons and because the risk for complications associated with these more extensive procedures is likely to be higher (110-119). We also excluded three studies that enrolled substantial numbers of participants who underwent VATS for indications other than pulmonary nodule diagnosis, such as pulmonary fibrosis, empyema, and recurrent pneumothorax (120-122) and two studies that did not report rates of specific complications (123, 124). The remaining four studies enrolled between 30 and 300 patients who underwent VATS wedge resection for pulmonary nodule diagnosis (59, 63, 65, 67). One study specified that consecutive patients were enrolled (59), two studies were retrospective case series, and one study involved voluntary reporting to a French registry (65). The mean age of participants ranged between 54 and 69 years.

In the four studies, the probability of serious, nonfatal complications ranged between 3% and 13%. Because sample size varied considerably across studies, we calculated the weighted mean probability of a nonfatal complication by first performing an arcsine transformation to stabilize the variance and then weighting studies by the inverse of the variance. We used the variance-stabilizing procedure because the variance of an observed proportion under 0.5 decreases as the magnitude of the proportion decreases, which might have biased our weighted estimate (125). The weighted mean complication rate was 6.5%. The probability of fatal complications ranged between 0% and 1.6%. The weighted mean fatal complication rate was 0.5%, which roughly corresponded to the reported frequency in the voluntary French registry.

To estimate the risk for fatal and nonfatal complications after thoracotomy, we identified two studies that examined postoperative outcomes in community settings. One observational study used discharge abstracts from California hospitals to identify 12 439 patients who underwent lung resection for cancer, 6569 of whom underwent lobectomy (62). In this study, the probability of in-hospital death from lobectomy was 4.2%, which we used as our base-case estimate. Lower postoperative mortality rates for lobectomy (1.6% to 3%) have been reported in tertiary care settings (60, 61, 64). Another study compared rates of serious, nonfatal complications in lung resections that were performed by thoracic surgeons and general surgeons in South Carolina nonfederal hospitals (66). In this study, the probability of serious, nonfatal postoperative complications after lobectomy performed by thoracic surgeons was 8.4%, which we used as our base-case estimate. The complication rate after lobectomy performed by general surgeons was 11%. In tertiary care settings, recent studies reported rates of nonfatal complications between 4.8% and 9%, but these reports did not distinguish between complications that occurred after lobectomy, pneumonectomy, or wedge resection (64, 126).

Costs. We converted all costs to 2001 U.S. dollars by using the gross domestic product deflator. Unlike the medical component of the Consumer Price Index, the gross domestic product deflator accounts for improvements in productivity. An index that does not account for technological change can seriously overestimate the true rate of inflation (127). In addition, the gross domestic product deflator considers all domestic economic activity, while the Consumer Price Index only includes spending by households.

Cost estimates for imaging tests, needle biopsy, and physician and pathologist services were based on Medicare reimbursement rates (70, 71), which are believed to be a good proxy for true opportunity costs (10). More specific information on hospital costs for surgical procedures was obtained from the Health Care Utilization Project (HCUP), which included data from 6.2 million discharges in 22 states in 1996 (72). Base-case estimates for costs are listed in Appendix Table 1.

Costs for noncontrast CT were $286 (Current Procedural Terminology [CPT] 71250), while costs for FDG-PET were $1980 (CPT G0125). To calculate costs for patients who were managed by watchful waiting, we added $34 for chest radiography (CPT 71020) and $38 for an outpatient office visit (CPT 99213) for each observation period. To calculate the cost of CT-guided needle biopsy ($583), we added procedure costs for percutaneous needle biopsy (CPT 32405), costs for CT guidance (CPT 76360), and pathology fees (CPT 88171). Costs for fluoroscope-guided needle biopsy were lower ($283). Costs for minor pneumothorax after needle biopsy were $72, including $34 for chest radiography and $38 for an outpatient office visit. Costs for chest tube drainage were $2566, including $2394 for 4 days of hospital care for iatrogenic pneumothorax (diagnosis-related group [DRG] 095) and $171 for physician services, including an initial evaluation (CPT 99221) and 3 days of subsequent hospital care (CPT 99231).

To calculate the cost of surgery for patients with malignant and benign nodules, we added hospital and professional fees. For patients with malignant nodules, we added the median cost-adjusted hospital charges for 3836 patients with lung cancer who underwent lobectomy from the HCUP database, and Medicare reimbursement for surgical lobectomy (CPT 32480) and pathologic interpretation (CPT 88309). Total surgical costs for patients with malignant nodules were $14 875. For patients with benign nodules, we added the median cost-adjusted hospital charges for 73 patients who underwent thoracoscopy for a benign diagnosis and Medicare reimbursement for surgical thoracoscopy with biopsy (CPT 32602) and pathologic interpretation (CPT 88307). Total surgical costs for patients with benign nodules were $11 625. To estimate costs for major surgical complications, we subtracted the mean Medicare reimbursement for lung biopsy without complications (DRG 077) from the mean reimbursement for lung biopsy with complications (DRG 076).

To estimate long-term health care costs for patients with surgically treated local lung cancer, surgically staged regional lung cancer, and distant-stage lung cancer, we used Medicare claims data for the years 1990 to 1993 (73). Average monthly costs for the first year after diagnosis are illustrated in Appendix Figure 8. To avoid counting costs for surgery twice, we subtracted surgical costs from the total costs for months 1 through 3. For years 2 to 5 after diagnosis, average monthly costs were $762, $934, and $1425 for patients with local, regional, and distant disease, respectively. To estimate health care costs for patients with benign nodules and for patients with malignant nodules more than 5 years after diagnosis, we used age-specific, average, annual health care expenditures from the U.S. Bureau of Labor Statistics (74).

Appendix (Figure 8).

Health care costs for patients with malignant pulmonary nodules.black circlesblack squaresblack triangles

Utilities. To identify studies that measured utilities (preference-based weights for health states) in patients with undiagnosed pulmonary nodules, we searched MEDLINE for English-language studies published before January 2000 by combining the MeSH terms and keywords health status, health status indicators, quality of life, standard gamble, and time tradeoff with a list of MeSH terms and keywords for lung cancer and pulmonary nodules. We updated the literature search in November 2001. We also scanned a comprehensive library of 1000 health-related quality-of-life estimates (128). Because we could not identify studies that examined the preferences of patients with pulmonary nodules who were managed by watchful waiting, we assumed that the relative utility of the time spent in observation was normal, and therefore used age- and sex-specific values from the Beaver Dam Health Outcomes study (75). To account for the possibility that some patients might be uncomfortable not knowing whether a nodule was benign or malignant, we tested lower utility values in a sensitivity analysis. We believe it is likely that preferences will vary between patients, depending on factors such as the probability of malignancy, the duration of time spent in observation, and the patient's risk attitude.

We used age- and sex-specific values to estimate utilities for patients with local-stage malignant nodules because in two studies of outcomes after thoracotomy for lung cancer, health-related quality of life returned to baseline within 3 months of surgery (129, 130). To obtain utilities for patients with regional-stage, distant-stage, or recurrent lung cancer, we multiplied the age- and sex-specific value by a relative utility of 0.7. This value was taken from an economic evaluation that compared different chemotherapy regimens in patients with metastatic nonsmall-cell lung cancer, in which 14 oncology physicians and nurses reported that their utility for chemotherapy was 0.7 (76).

We adjusted quality of life for time spent in the hospital and time spent having diagnostic procedures. When possible, we used data on average length of hospital stay to make these adjustments (71).

Time Preference

We discounted all costs and health effects at an annual rate of 3% and tested discount rates between 0% and 5% in sensitivity analysis (10).

Analytical Plan

We stratified the hypothetical study cohort according to the pretest probability of malignancy and the risk for postoperative complications. Postoperative complications included both fatal and nonfatal complications after either VATS biopsy or lobectomy. We performed separate analyses for six combinations of pretest probability (low, intermediate, and high) and surgical risk (average and high). We selected probabilities of 26%, 55%, and 79% to represent patients with low, intermediate, and high pretest probability, respectively. We used the base-case values and upper ranges to represent patients at average and high risk for surgical complications, respectively. Because the probabilities of fatal and nonfatal surgical complications are likely to be highly correlated, we did not vary them independently. Instead, we assumed that they were completely correlated and bundled them together in groups.

Several quantitative models exist for estimating pretest probability (5, 21, 131, 132). Readers who wish to apply our results may benefit from using such a model to estimate pretest probability in individual patients. The best available model used multivariable logistic regression to identify six independent predictors of malignancy: age, smoking status, history of cancer, nodule diameter, spiculation, and upper lobe location (21). This clinical prediction rule was derived from a cohort of 629 patients with newly discovered pulmonary nodules measuring 4 to 20 mm in diameter who were evaluated at the Mayo Clinic between 1 January 1984 and 1 May 1986. The prevalence of malignancy was 26.4%. Two thirds of the observations were used to develop the model and the remaining observations were used as a validation set.

These equations can be used to calculate the pretest probability of malignancy:

where age is the patient's age in years, smoking = 1 if the patient is a current or former smoker (otherwise 0), cancer = 1 if the patient has a history of an extrathoracic cancer that was diagnosed more than 5 years ago (otherwise = 0), diameter is the diameter of the nodule in millimeters, spiculation = 1 if the edge of the nodule has spicules (otherwise = 0), and upper = 1 if the nodule is located in an upper lobe (otherwise = 0). To calculate pretest probability in individual patients, equations (1) and (2) can be entered into a personal digital assistant for use in the office or clinic. Unfortunately, it is not possible to calculate CIs for the predicted pretest probability based on the information provided because the developers of the model did not provide the covariance matrix for parameter estimates. Of note, age and history of cancer were not found to be independent predictors of malignancy in the validation set.

The ROC curve analysis indicated that the model had very good predictive accuracy in both the derivation set (area under the curve, 0.83) and the validation set (area under the curve, 0.80). An area under the curve of 1.0 indicates perfect accuracy in prediction, while an area under the curve of 0.5 indicates that the prediction is no more accurate than a coin flip. The goodness-of-fit statistics for the model derivation and validation sets indicated that the observed proportion of patients with malignancy did not differ from the predicted proportion (chi-square = 5.085, P = 0.75; and chi-square = 6.221, P = 0.62; respectively). A calibration curve indicated that the numbers of observed and predicted cases of cancer were the same across the entire range of the probability of malignancy.

Knowing that most physicians rely on clinical intuition and judgment to estimate pretest probability, the developers of the model used ROC analysis to compare estimates of the probability of cancer obtained by using the prediction equation with those made by four experienced clinicians at the Mayo Clinic, including a radiologist, pulmonologist, general internist, and thoracic surgeon (133). Areas under the ROC curves for each of the physicians were slightly greater than the area under the curve for the prediction equation, but these differences were not statistically significant. Relative to the prediction equation, physicians tended to overestimate pretest probability, particularly at lower values of predicted probability. Of interest, the four clinicians recommended a management strategy of observation in a very high percentage of cases (37%, 57%, 8%, and 35%, respectively) despite overestimating pretest probability. Predictions of pretest probability made by less experienced clinicians may not be as accurate as those made by these experts.

Two other quantitative models have been developed by using less rigorous methods and have not been validated (5, 131, 132). In addition, several groups have developed neural networks to assist in pulmonary nodule diagnosis. We are not aware of any published models that help to estimate the risk for complications for patients undergoing VATS biopsy or lobectomy.

Calculation of Incremental Cost-Effectiveness Ratios

We calculated incremental cost-effectiveness ratios by comparing strategies with the next most effective alternative, after eliminating strategies that were dominated. We considered all clinically plausible combinations of diagnostic tests because the cost-effectiveness of an intervention can be overestimated by comparing it with a suboptimal alternative. We eliminated strategies by strict dominance when an alternative strategy was both less costly and more effective. Strategies were eliminated by extended dominance when a more effective strategy had a more favorable incremental cost-effectiveness ratio (134). To calculate incremental cost-effectiveness ratios, we used the formula (C₁C₂)/(E₁E₂), where C₁ and C₂ represent total discounted lifetime health care costs associated with two different strategies for pulmonary nodule diagnosis in 2001 dollars, and E₁ and E₂ are outcomes associated with the two strategies, measured in discounted QALYs.

Sensitivity Analysis

We performed one-way and multiway sensitivity analyses to identify important model uncertainties. When possible, ranges for variables were based on reported or calculated 95% CIs for means and interquartile ranges for medians. For diagnostic accuracy, we tested several points on summary ROC curves and their 95% CIs. We used clinical judgment to determine ranges for utilities. For costs, we determined ranges by adding or subtracting 25% from the base case estimate. To determine ranges for transition probabilities in the Markov model, we added or subtracted 50% from the base-case estimate because these estimates were more uncertain.

We performed probabilistic sensitivity analysis by stratifying patients according to pretest probability and the risk for surgical complications. We assigned logit-normal distributions to all probabilities and costs for all diagnostic test variables by using the method of Doubilet and colleagues (77) and then performed 10 000 simulations by randomly sampling values from these distributions. Logit-normal distributions have two main advantages: The full distribution can be approximated from a specified mean (base-case value) and an upper or lower bound, and the mean of the distribution function equals the base-case value. Thus, the mean value of the expected utility of each strategy in probabilistic analysis will ultimately converge to its expected value in the corresponding deterministic model (77). To account for correlation between sensitivity and specificity, we sampled values from a logit-normal distribution that we assigned to describe the specificity of a diagnostic test and used a formula to identify the corresponding sensitivity on the summary ROC curve.

For the purpose of the probabilistic analyses, we assumed that the hypothetical study cohort was infinitely large. Thus, while the probabilistic analysis accounted for second-order uncertainty (uncertainty in the values of model parameters), it did not account for first-order uncertainty (uncertainty related to sampling variability that would occur in a finite-sized population). This type of uncertainty can affect the magnitude of cost-effectiveness ratios when sampling from populations that are finite in size (135). While this source of uncertainty is not likely to be important for policy decisions made at a national level, it may be important for decisions that are made at the hospital or departmental level. In these settings, the cost-effectiveness ratios might differ because of sampling variation.

To account for uncertainty in the natural history of lung cancer, we performed a separate set of probabilistic analyses stratified by pretest probability in which we adopted the less pessimistic assumptions of Cummings and colleagues (9) and Gambhir and colleagues (81) on the negative consequences of delayed diagnosis in patients with malignant nodules who were managed by observation at some point in their evaluation. To do this, we reduced the probabilities of disease progression from local to regional to distant lung cancer during the observation period by 50%, which replicated the 14% reduction in life expectancy that Gambhir and colleagues predicted would result if diagnosis and treatment were delayed by one doubling time.

Software

We used Decision Maker software (Pratt Medical Group, Boston, Massachusetts) to create the Markov model. The Markov model generated long-term costs and QALYs for patients with malignant and benign nodules who, after preliminary diagnostic testing, were managed by either surgery or watchful waiting. Although this submodel did not include diagnostic testing variables, we also constructed a complete version of the model in Decision Maker. Because the complete Decision Maker model contained several embedded decision nodes, it was difficult to interpret the results of numerous sensitivity analyses. Therefore, we imported the long-term costs and QALYs that were generated by the Decision Maker submodel into a spreadsheet version of the full model (Excel 2000, Microsoft, Inc., Redmond, Washington). Costs and QALYs associated with each strategy were calculated by the spreadsheet, plotted to define the efficiency frontier, and sorted to calculate appropriate incremental cost-effectiveness ratios. To perform probabilistic sensitivity analysis, we used Crystal Ball 2000 standard edition simulation software (Decisioneering, Inc., Denver, Colorado).

Before running analyses, we extensively tested the model by entering extreme values for variables and checking to make sure that the model generated expected results. For example, watchful waiting was the dominant strategy when we assumed that delayed diagnosis and treatment were not associated with any reduction in life expectancy. Similarly, surgery without any diagnostic testing was the most effective strategy when we assumed that the probability of fatal and nonfatal surgical complications was zero. We also compared the results of base-case models constructed with Decision Maker and Excel and found that they were identical.

Results

We first present results of the Markov model, which generated total lifetime health care costs and QALYs for patients with malignant and benign nodules, independent of any diagnostic testing. Next, we report the results of selected sensitivity analyses, including the results of probabilistic analyses. Readers should consult the print version of the manuscript for base-case results and results of one-way sensitivity analysis.

Estimating Costs and QALYs for Patients with Malignant and Benign Nodules

The Markov model estimated lifetime costs and QALYs for patients with malignant and benign nodules who, after preliminary testing, were managed by either surgery or watchful waiting. Under the assumptions of the Markov model and not including costs for other diagnostic tests, total discounted costs and QALYs were approximately $75 200 and 6.57 QALYs for patients with malignant nodules who were managed by surgery, $67 100 and 5.09 QALYs for patients with malignant nodules in whom surgery was delayed because of watchful waiting, $50 600 and 11.80 QALYs for patients with benign nodules who underwent unnecessary surgery, and $43 500 and 11.85 QALYs for patients with benign nodules who were managed by watchful waiting. Thus, QALYs were reduced by 23% in patients with malignant nodules who were managed by watchful waiting at some point in their evaluation. In contrast, QALYs were reduced by only 0.4% in patients with benign nodules who underwent unnecessary surgery. This indicates that the consequences of false-negative diagnostic testing (delayed diagnosis and treatment) are much more serious than the consequences of false-positive testing (unnecessary surgery). Although total lifetime costs for patients with malignant nodules who were managed by watchful waiting were lower than costs for patients with malignant nodules who underwent surgery without delay, average annual health care costs were higher in the group that underwent watchful waiting ($13 200 versus $11 400). In patients with benign nodules, unnecessary surgery was associated with a 14% increase in total discounted health care costs. Estimates of costs and QALYs generated by the Markov model were entered into the larger decision model.

Threshold Analysis

Influence of Pretest Probability. We determined threshold values for when to use specific tests as a function of pretest probability (Appendix Figures 9 and 10). Because our results indicated that CT should be used as the first test in almost all circumstances, we also describe thresholds in terms of post-test probability after CT.

Appendix (Figure 9).

Recommended sequence of diagnostic testing in patients who are at average risk for surgical complications, according to pretest probability, computed tomography (CT) results, and threshold that determines cost-effectiveness.QALYPET

Appendix (Figure 10).

Recommended sequence of diagnostic testing in patients who are at high risk for surgical complications, according to pretest probability, computed tomography (CT) results, and threshold that determines cost-effectiveness.FDG-PETQALY

For patients who were at average risk for surgical complications, use of FDG-PET cost less than $100 000 per QALY gained when pretest probability was low (10% to 50%) and CT results were possibly malignant, or when pretest probability was high (77% to 89%) and CT results were benign (Appendix Figure 9). Both of these situations resulted in intermediate post-test probabilities (20% to 69%). Surgery was favored at higher post-test probabilities ( 70%), biopsy was preferred at lower post-test probabilities (2% to 20%), and watchful waiting was preferred only when post-test probability was very low (<2%). Threshold values were similar when we used $50 000 per QALY as the cut-point for societal willingness to pay, although FDG-PET was recommended across a slightly narrower range of post-test probabilities (20% to 64%).

In patients at high risk for surgical complications, use of FDG-PET cost less than $100 000 per QALY gained when post-test probability ranged between 35% and 86% (Appendix Figure 10). Surgery was favored at higher post-test probabilities ( 87%), biopsy was favored when post-test probability was low (2% to 34%), and watchful waiting was preferred only when post-test probability was very low (<2%). Thus, the range of post-test probabilities at which FDG-PET is recommended shifts to higher values when the risk for surgical complications is high. Once again, threshold values were similar when we used $50 000 per QALY as the cut-point for societal willingness to pay, although in this case FDG-PET was recommended across a much narrower range of post-test probabilities (48% to 76%).

Sensitivity Analysis

Influence of Conditional Test Performance. To examine the potential effect of conditional test performance, we assumed that FDG-PET was 25% less sensitive and 16% more specific when CT results were benign, as observed in studies of FDG-PET and CT for mediastinal staging in patients with nonsmall-cell lung cancer (78). Because false-negative test results produce much greater reductions in life expectancy than false-positive results, varying sensitivity will have a much greater effect than varying specificity. In patients with low or intermediate pretest probability, decreasing the conditional sensitivity of FDG-PET (conditioned on benign CT results) should not have an effect on whether FDG-PET is used because FDG-PET strategies were not recommended when CT results were benign in this group of patients. Reducing the conditional sensitivity of FDG-PET could only strengthen the recommendation against its use. However, in patients with high pretest probability, selective use of FDG-PET was recommended when CT results were benign in the base-case analysis. In this situation, reducing the (conditional) sensitivity of FDG-PET might lead to a different choice of strategies. Nevertheless, we found that this was not the case, even when we assumed that conditional sensitivity of FDG-PET was reduced by 25%. In fact, we obtained results that were very similar to the base-case results, even when we assumed that the specificity of FDG-PET was 16% higher than the base-case estimate and that sensitivity was as low as 50% (base-case sensitivity, 94.2%).

Sensitivity Analysis

Effect of Dynamic CT. To examine the potential role of contrast-enhanced dynamic CT, we evaluated six additional strategies that used this test. In all six cases, dynamic CT was used only when the results of non-contrast CT were possibly malignant. We assumed that the sensitivity and specificity of dynamic CT were 98% and 58%, respectively (108) and that the cost was the same as for chest CT with contrast ($334). In patients with intermediate pretest probability (55%), a dynamic CT-based strategy was more effective and less expensive than almost all PET-based strategies. In this strategy, needle biopsy was performed when the results of non-contrast CT were benign or when the results of dynamic CT were negative (<15 HU enhancement) and surgery was performed when the results of dynamic CT were positive. This strategy cost less than $15 000 per QALY gained relative to a similar but slightly less aggressive strategy that included watchful waiting when dynamic CT results were negative. A strategy that used PET nonselectively in all patients was most effective, but cost more than $2 000 000 per QALY gained. In patients with low pretest probability (26%), these same two dynamic CT-based strategies were highly effective and cost less than $50 000 per QALY gained. However, in patients with high pretest probability (79%), FDG-PET strategies were more effective than dynamic CT-based strategies, and cost between $15 000 and $65 000 per QALY gained. These preliminary findings suggest that dynamic CT with contrast enhancement is potentially highly cost-effective in patients with low and intermediate pretest probability of malignancy, but not in patients with high pretest probability.

Probabilistic Analysis. We describe the results of probabilistic analyses for patients with low, intermediate, and high pretest probability of malignancy. We further stratify the cohort according to the risk for surgical complications. Probabilistic analysis provided estimates of uncertainty for our calculated cost-effectiveness ratios. On the basis of the results of 10 000 simulations, we report the percentage of simulations in which the strategy under consideration was more effective and more expensive (quadrant I), less effective and more expensive (quadrant II), less effective and less expensive (quadrant III), and more effective and less expensive (quadrant IV) than the alternative. We use the term cost saving to describe results that fall in quadrant IV.

Low Pretest Probability: In patients with low pretest probability (26%) who were at average risk for surgical complications, watchful waiting was the least expensive and least effective strategy (Appendix Table 9). A strategy that used CT but not PET (strategy 7) was more effective and cost less than $100 000 per QALY gained in 100% of all simulations. A strategy that used FDG-PET selectively when CT results were possibly malignant (strategy 12) was more effective and was either less expensive (quadrant IV) or cost less than $100 000 per QALY gained (quadrant I) in almost 77% of all simulations. This strategy used surgery when FDG-PET results were positive, needle biopsy when FDG-PET results were negative, and watchful waiting when CT results were benign. A similar strategy that used needle biopsy rather than observation when CT results were benign (strategy 15) was even more effective and cost less than $100 000 per QALY gained relative to its less aggressive counterpart in almost 69% of all simulations. Thus, it appears that using needle biopsy rather than watchful waiting may be economically attractive when CT results are benign. In contrast, a strategy that used FDG-PET nonselectively in all patients (strategy 35) was either less effective than the alternative or cost more than $100 000 per QALY gained in almost 85% of simulations.

Appendix Table 9. Expected Costs, Quality-Adjusted Life-Years, and Incremental Cost-Effectiveness Ratios in Patients with Low Pretest Probability (26%) and Average Risk for Surgical Complications

Results were similar for patients with low pretest probability (26%) who were at high risk for surgical complications (Appendix Table 10). A strategy that used FDG-PET selectively when CT results were possibly malignant (strategy 15) was either cost saving (quadrant IV) or cost less than $100 000 per QALY gained in 66% of simulations, relative to the most effective strategy that did not include FDG-PET. In this strategy, surgery was performed when FDG-PET results were positive, and needle biopsy was performed when FDG-PET results were negative or when CT results were benign. Thus, selective use of FDG-PET appeared to be slightly less attractive economically in these high-risk surgical patients when compared with patients whose risk for surgical complications was average. This finding makes sense because the main benefit of FDG-PET imaging in patients with low pretest probability is to identify patients with hypermetabolic nodules and send them directly to surgery. Thus, use of FDG-PET is slightly less attractive in patients with low pretest probability when the risk for surgical complications is high.

Appendix Table 10. Expected Costs, Quality-Adjusted Life-Years, and Incremental Cost-Effectiveness Ratios in Patients with Low Pretest Probability (26%) and High Risk for Surgical Complications

Intermediate Pretest Probability: For patients with intermediate pretest probability (55%) who were at average risk for surgical complications, the least effective and least expensive strategy was watchful waiting (Appendix Table 11). Three strategies that included CT, but not FDG-PET, were more effective and cost less than $20 000 per QALY gained. The most effective of these strategies used surgery when CT results were possibly malignant and needle biopsy when CT results were benign (strategy 6). This strategy was either cost saving or cost less than $100 000 per QALY gained in more than 85% of all simulations. A strategy that used FDG-PET selectively when CT results were possibly malignant (strategy 15) was slightly more effective, but this strategy was either less effective and more expensive (quadrant II) than the alternative, or cost more than $100 000 per QALY gained in more than 75% of all simulations. This confirms that FDG-PET strategies are less attractive economically in patients with intermediate pretest probability, as we found in the deterministic analysis.

Appendix Table 11. Expected Costs, Quality-Adjusted Life-Years, and Incremental Cost-Effectiveness Ratios in Patients with Intermediate Pretest Probability (55%) and Average Risk for Surgical Complications

Appendix Table 11. Expected Costs, Quality-Adjusted Life-Years, and Incremental Cost-Effectiveness Ratios in Patients with Intermediate Pretest Probability (55%) and Average Risk for Surgical Complications

In patients with intermediate pretest probability (55%) who were at high risk for surgical complications, a strategy that used FDG-PET selectively when CT results were possibly malignant (strategy 15) cost less than $100 000 per QALY gained relative to the most effective strategy that did not use FDG-PET in 86% of all simulations (Appendix Table 12). In this strategy, surgery was performed when FDG-PET results were positive and needle biopsy was performed when FDG-PET results were negative or when CT results were benign. Thus, as in the deterministic analysis, probabilistic analysis suggested that selective use of FDG-PET was more attractive economically in patients with intermediate pretest probability when the risk for surgical complications was high.

Appendix Table 12. Expected Costs, Quality-Adjusted Life-Years, and Incremental Cost-Effectiveness Ratios in Patients with Intermediate Pretest Probability (55%) and High Risk for Surgical Complications

Appendix Table 12. Expected Costs, Quality-Adjusted Life-Years, and Incremental Cost-Effectiveness Ratios in Patients with Intermediate Pretest Probability (55%) and High Risk for Surgical Complications

High Pretest Probability: For patients with high pretest probability (79%) who were at average risk for surgical complications, watchful waiting was again the least effective and least expensive strategy (Appendix Table 13). A strategy that used CT but not FDG-PET (strategy 5) was much more effective and cost less than $100 000 per QALY gained relative to watchful waiting in 100% of all simulations. However, three strategies that used FDG-PET selectively when CT results were benign were even more effective. The least aggressive of these strategies used surgery when CT results were possibly malignant, needle biopsy when FDG-PET results were positive, and watchful waiting when FDG-PET results were negative (strategy 19). Relative to the most effective CT-based strategy, this strategy cost less than $100 000 per QALY gained in 99% of all simulations. Two other PET strategies were marginally more effective and slightly more expensive (strategies 18 and 17). One of these strategies used surgery when FDG-PET results were positive and watchful waiting when FDG-PET results were negative. The more aggressive strategy used needle biopsy when FDG-PET results were negative. In more than 40% of all simulations, these strategies were less effective and more expensive than the alternative (quadrant II) or cost more than $100 000 per QALY gained. This is because there were only marginal differences amongst the three PET-based strategies with respect to expected costs and outcomes. Thus, these approaches are roughly equivalent and other factors should be considered when deciding between them, such as the expected yield of needle biopsy and patient preferences.

Appendix Table 13. Expected Costs, Quality-Adjusted Life-Years, and Incremental Cost-Effectiveness Ratios in Patients with High Pretest Probability (79%) and Average Risk for Surgical Complications

For patients with high pretest probability (79%), strategies that use FDG-PET appeared to be less attractive economically when the risk for surgical complications was high (Appendix Table 14). A strategy that included FDG-PET selectively when CT results were benign (strategy 17) was only marginally more effective than the most effective CT-based approach (strategy 6). The CT-based strategy used surgery when CT results were possibly malignant and needle biopsy when CT results were benign. In more than 80% of simulations, the selective PET strategy was less effective and more expensive than the CT-based approach (quadrant II) or cost more than $100 000 per QALY gained. Thus, selective use of FDG-PET is considerably less attractive economically in patients with high pretest probability when the risk for surgical complications is high.

Appendix Table 14. Expected Costs, Quality-Adjusted Life-Years, and Incremental Cost-Effectiveness Ratios in Patients with High Pretest Probability (79%) and High Risk for Surgical Complications

Clinical Implications

1. Patients with new, noncalcified solitary pulmonary nodules should be stratified according to the pretest probability of malignancy and the risk for surgical complications. Computed tomography should be performed to confirm the presence of an intraparenchymal nodule, to define the location and edge characteristics of the lesion, and to assess whether hilar or mediastinal lymph nodes are enlarged. Computed tomography infrequently identifies smooth borders and occult calcification that are highly suggestive of a benign diagnosis.

2. Nonselective use of FDG-PET for pulmonary nodule diagnosis is highly effective, provided that the results are interpreted correctly and followed by appropriate interventions (for example, watchful waiting or needle biopsy when FDG-PET results are negative, or surgery or needle biopsy when FDG-PET results are positive). However, strategies that use FDG-PET nonselectively are expensive and do not seem to represent an efficient use of health care resources.

3. For clinicians who wish to make efficient use of health care resources, it is most cost-effective to use FDG-PET when pretest probability and CT results are discordant (that is, when pretest probability is low and CT results are possibly malignant, or when pretest probability is high and CT results are benign). In these cases, post-test probability after CT falls in an intermediate range (20% to 69%). Because CT results are most often possibly malignant (indeterminate), the typical indication for FDG-PET imaging will be in a patient with low pretest probability and possibly malignant results on CT. The main reason why FDG-PET strategies are beneficial in patients with low pretest probability is because they identify individuals with hypermetabolic nodules and send them directly to surgery. In patients who are at high risk for surgical complications, the range of post-test probabilities at which FDG-PET strategies cost less than $100 000 per QALY gained shifts to higher values (35% to 84%).

4. Positron emission tomography with 18-fluorodeoxyglucose strategies cost more than $200 000 per QALY gained when pretest probability of malignancy is intermediate. In these patients, post-test probability is low when CT results are benign and post-test probability is high when CT results are possibly malignant. Use of FDG-PET in these situations provides little additional benefit at a considerable additional cost.

5. Once the results of imaging studies are known, aggressive use of surgery and needle biopsy is both highly effective and highly cost-effective. For example, use of needle biopsy when FDG-PET results are negative is not only more effective than watchful waiting but is highly cost effective. Likewise, when FDG-PET results are positive, surgery is typically more effective than needle biopsy. Aggressive use of surgery and needle biopsy serves to reduce false-negative diagnostic evaluations. This is important because false-negative evaluations lead to delayed diagnosis, missed opportunities for surgical cure, and large reductions in QALYs. By comparison, the consequences of unnecessary surgery in patients with false-positive diagnostic evaluations are relatively minor.

6. Other factors that should be considered when managing patients with pulmonary nodules include the risk for surgical complications, the probability of nondiagnostic biopsy, local availability and experience in the use of imaging tests, and patient preferences. The risk for surgical complications and the probability of nondiagnostic biopsy depend on both patient factors and operator experience.

Policy Implications

Selective use of FDG-PET imaging for pulmonary nodule diagnosis represents a good value for the health care dollar relative to other commonly accepted medical and public health interventions.
Dissemination of FDG-PET imaging for diagnosis of pulmonary nodules is worthwhile based on efficiency criteria.
Current policies that deny reimbursement for needle biopsy after FDG-PET should be reconsidered. When FDG-PET results are negative, it is usually more effective to perform needle biopsy rather than watchful waiting, except when pretest probability is very low.
Computed tomography with dynamic contrast enhancement seems to be a promising alternative to FDG-PET that warrants further study. It seems to be most cost-effective when used selectively in patients with low to intermediate pretest probability who have possibly malignant results on noncontrast CT.

References

Ost
D
,
Fein
A
.
Evaluation and management of the solitary pulmonary nodule
Am J Respir Crit Care Med
2000
162
782
7
PubMed
CrossRef

PubMed
Khan
A
,
Herman
PG
,
Vorwerk
P
,
Stevens
P
,
Rojas
KA
,
Graver
M
.
Solitary pulmonary nodules: comparison of classification with standard, thin-section, and reference phantom CT
Radiology
1991
179
477
81
PubMed
CrossRef

PubMed
Swensen
SJ
,
Morin
RL
,
Schueler
BA
,
Brown
LR
,
Cortese
DA
,
Pairolero
PC
,
et al.
.
Solitary pulmonary nodule: CT evaluation of enhancement with iodinated contrast materiala preliminary report
Radiology
1992
182
343
7
PubMed
CrossRef

PubMed
Siegelman
SS
,
Khouri
NF
,
Leo
FP
,
Fishman
EK
,
Braverman
RM
,
Zerhouni
EA
.
Solitary pulmonary nodules: CT assessment
Radiology
1986
160
307
12
PubMed
CrossRef

PubMed
Gurney
JW
.
Determining the likelihood of malignancy in solitary pulmonary nodules with Bayesian analysis. Part I. Theory
Radiology
1993
186
405
13
PubMed
CrossRef

PubMed
Cook
GJ
,
Maisey
MN
.
The current status of clinical PET imaging
Clin Radiol
1996
51
603
13
PubMed
CrossRef

PubMed
Lowe
VJ
,
Naunheim
KS
.
Current role of positron emission tomography in thoracic oncology
Thorax
1998
53
703
12
PubMed
CrossRef

PubMed
Patz
EF
Jr
,
Goodman
PC
.
Positron emission tomography imaging of the thorax
Radiol Clin North Am
1994
32
811
23
PubMed
PubMed
Cummings
SR
,
Lillington
GA
,
Richard
RJ
.
Managing solitary pulmonary nodules. The choice of strategy is a close call.
Am Rev Respir Dis
1986
134
453
60
PubMed
PubMed
Cost-Effectiveness in Health and Medicine
New York
Oxford Univ Pr
1996
National Cancer Institute. Surveillance, Epidemiology and End Results. Accessed at seer.cancer.gov on 4 December 2002.
Libshitz
HI
,
McKenna
RJ
Jr
,
Haynie
TP
,
McMurtrey
MJ
,
Mountain
CT
.
Mediastinal evaluation in lung cancer
Radiology
1984
151
295
9
PubMed
CrossRef

PubMed
Graves
WG
,
Martinez
MJ
,
Carter
PL
,
Barry
MJ
,
Clarke
JS
.
The value of computed tomography in staging bronchogenic carcinoma: a changing role for mediastinoscopy
Ann Thorac Surg
1985
40
57
9
PubMed
CrossRef

PubMed
McKenna
RJ
Jr
,
Libshitz
HI
,
Mountain
CE
,
McMurtrey
MJ
.
Roentgenographic evaluation of mediastinal nodes for preoperative assessment in lung cancer
Chest
1985
88
206
10
PubMed
CrossRef

PubMed
Pearlberg
JL
,
Sandler
MA
,
Beute
GH
,
Madrazo
BL
.
T1N0M0 bronchogenic carcinoma: assessment by CT
Radiology
1985
157
187
90
PubMed
CrossRef

PubMed
Heavey
LR
,
Glazer
GM
,
Gross
BH
,
Francis
IR
,
Orringer
MB
.
The role of CT in staging radiographic T1N0M0 lung cancer
AJR Am J Roentgenol
1986
146
285
90
PubMed
CrossRef

PubMed
Conces
DJ
Jr
,
Klink
JF
,
Tarver
RD
,
Moak
GD
.
T1N0M0 lung cancer: evaluation with CT
Radiology
1989
170
643
6
PubMed
CrossRef

PubMed
Becker
GL
,
Whitlock
WL
,
Schaefer
PS
,
Tenholder
MF
.
The impact of thoracic computed tomography in clinically staged T1, N0, M0 chest lesions
Arch Intern Med
1990
150
557
9
PubMed
CrossRef

PubMed
Seely
JM
,
Mayo
JR
,
Miller
RR
,
Mller
NL
.
T1 lung cancer: prevalence of mediastinal nodal metastases and diagnostic accuracy of CT
Radiology
1993
186
129
32
PubMed
CrossRef

PubMed
Steele
JD
,
Buell
P
.
Asymptomatic solitary pulmonary nodules. Host survival, tumor size, and growth rate
J Thorac Cardiovasc Surg
1973
65
140
51
PubMed
PubMed
Swensen
SJ
,
Silverstein
MD
,
Ilstrup
DM
,
Schleck
CD
,
Edell
ES
.
The probability of malignancy in solitary pulmonary nodules. Application to small radiologically indeterminate nodules
Arch Intern Med
1997
157
849
55
PubMed
CrossRef

PubMed
Gould
MK
,
Maclean
CC
,
Kuschner
WG
,
Rydzak
CE
,
Owens
DK
.
Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis
JAMA
2001
285
914
24
PubMed
CrossRef

PubMed
Kubota
K
,
Matsuzawa
T
,
Fujiwara
T
,
Ito
M
,
Hatazawa
J
,
Ishiwata
K
,
et al.
.
Differential diagnosis of lung tumor with positron emission tomography: a prospective study
J Nucl Med
1990
31
1927
32
PubMed
PubMed
Gupta
NC
,
Frank
AR
,
Dewan
NA
,
Redepenning
LS
,
Rothberg
ML
,
Mailliard
JA
,
et al.
.
Solitary pulmonary nodules: detection of malignancy with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose
Radiology
1992
184
441
4
PubMed
CrossRef

PubMed
Dewan
NA
,
Gupta
NC
,
Redepenning
LS
,
Phalen
JJ
,
Frick
MP
.
Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules. Potential role in evaluation and management
Chest
1993
104
997
1002
PubMed
CrossRef

PubMed
Patz
EF
Jr
,
Lowe
VJ
,
Hoffman
JM
,
Paine
SS
,
Burrowes
P
,
Coleman
RE
,
et al.
.
Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning
Radiology
1993
188
487
90
PubMed
CrossRef

PubMed
Dewan
NA
,
Reeb
SD
,
Gupta
NC
,
Gobar
LS
,
Scott
WJ
.
PET-FDG imaging and transthoracic needle lung aspiration biopsy in evaluation of pulmonary lesions. A comparative riskbenefit analysis
Chest
1995
108
441
6
PubMed
CrossRef

PubMed
Duhaylongsod FG, Lowe VJ, Patz EF Jr, Vaughn AL, Coleman RE, Wolfe WG. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET). J Thorac Cardiovasc Surg. 1995; 110:130-9; discussion 139-40. [PMID: 7609536]
Duhaylongsod
FG
,
Lowe
VJ
,
Patz
EF
Jr
,
Vaughn
AL
,
Coleman
RE
,
Wolfe
WG
.
Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography
Ann Thorac Surg
1995
60
1348
52
PubMed
CrossRef

PubMed
Gupta
NC
,
Maloof
J
,
Gunel
E
.
Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET
J Nucl Med
1996
37
943
8
PubMed
PubMed
Dewan
NA
,
Shehan
CJ
,
Reeb
SD
,
Gobar
LS
,
Scott
WJ
,
Ryschon
K
.
Likelihood of malignancy in a solitary pulmonary nodule: comparison of Bayesian analysis and results of FDG-PET scan
Chest
1997
112
416
22
PubMed
CrossRef

PubMed
Gupta
N
,
Gill
H
,
Graeber
G
,
Bishop
H
,
Hurst
J
,
Stephens
T
.
Dynamic positron emission tomography with F-18 fluorodeoxyglucose imaging in differentiation of benign from malignant lung/mediastinal lesions
Chest
1998
114
1105
11
PubMed
CrossRef

PubMed
Lowe
VJ
,
Fletcher
JW
,
Gobar
L
,
Lawson
M
,
Kirchner
P
,
Valk
P
,
et al.
.
Prospective investigation of positron emission tomography in lung nodules
J Clin Oncol
1998
16
1075
84
PubMed
CrossRef

PubMed
Orino
K
,
Kawamura
M
,
Hatazawa
J
,
Suzuki
I
,
Sazawa
Y
.
[Efficacy of F-18 fluorodeoxyglucose positron emission tomography (FDG-PET) scans in diagnosis of pulmonary nodules]
Jpn J Thorac Cardiovasc Surg
1998
46
1267
74
PubMed
CrossRef

PubMed
Pruer
HW
,
Weber
WA
,
Rmer
W
,
Treumann
T
,
Ziegler
SI
,
Schwaiger
M
.
Controlled prospective study of positron emission tomography using the glucose analogue [18f]fluorodeoxyglucose in the evaluation of pulmonary nodules
Br J Surg
1998
85
1506
11
PubMed
CrossRef

PubMed
Moses
LE
,
Shapiro
D
,
Littenberg
B
.
Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations
Stat Med
1993
12
1293
316
PubMed
CrossRef

PubMed
Owens
DK
,
Holodniy
M
,
Garber
AM
,
Scott
J
,
Sonnad
S
,
Moses
L
,
et al.
.
Polymerase chain reaction for the diagnosis of HIV infection in adults. A meta-analysis with recommendations for clinical practice and study design
Ann Intern Med
1996
124
803
15
CrossRef

PubMed
Siegelman
SS
,
Zerhouni
EA
,
Leo
FP
,
Khouri
NF
,
Stitik
FP
.
CT of the solitary pulmonary nodule
AJR Am J Roentgenol
1980
135
1
13
PubMed
CrossRef

PubMed
Godwin
JD
,
Speckman
JM
,
Fram
EK
,
Johnson
GA
,
Putman
CE
,
Korobkin
M
,
et al.
.
Distinguishing benign from malignant pulmonary nodules by computed tomography
Radiology
1982
144
349
51
PubMed
CrossRef

PubMed
Zerhouni
EA
,
Boukadoum
M
,
Siddiky
MA
,
Newbold
JM
,
Stone
DC
,
Shirey
MP
,
et al.
.
A standard phantom for quantitative CT analysis of pulmonary nodules
Radiology
1983
149
767
73
PubMed
CrossRef

PubMed
Proto
AV
,
Thomas
SR
.
Pulmonary nodules studied by computed tomography
Radiology
1985
156
149
53
PubMed
CrossRef

PubMed
Zerhouni
EA
,
Stitik
FP
,
Siegelman
SS
,
Naidich
DP
,
Sagel
SS
,
Proto
AV
,
et al.
.
CT of the pulmonary nodule: a cooperative study
Radiology
1986
160
319
27
PubMed
CrossRef

PubMed
Huston
J
3rd
,
Muhm
JR
.
Solitary pulmonary nodules: evaluation with a CT reference phantom
Radiology
1989
170
653
6
PubMed
CrossRef

PubMed
Jones
FA
,
Wiedemann
HP
,
O'Donovan
PB
,
Stoller
JK
.
Computerized tomographic densitometry of the solitary pulmonary nodule using a nodule phantom
Chest
1989
96
779
83
PubMed
CrossRef

PubMed
Ward HB, Pliego M, Diefenthal HC, Humphrey EW. The impact of phantom CT scanning on surgery for the solitary pulmonary nodule. Surgery. 1989; 106:734-8; discussion 738-9. [PMID: 2799649]
Takanashi
N
,
Nobe
Y
,
Asoh
H
,
Yano
T
,
Ichinose
Y
.
The diagnostic accuracy of a solitary pulmonary nodule, using thin-section high resolution CT: a solitary pulmonary nodule by HRCT
Lung Cancer
1995
13
105
12
PubMed
CrossRef

PubMed
Seemann
MD
,
Staebler
A
,
Beinert
T
,
Dienemann
H
,
Obst
B
,
Matzko
M
,
et al.
.
Usefulness of morphological characteristics for the differentiation of benign from malignant solitary pulmonary lesions using HRCT
Eur Radiol
1999
9
409
17
PubMed
CrossRef

PubMed
vanSonnenberg
E
,
Casola
G
,
Ho
M
,
Neff
CC
,
Varney
RR
,
Wittich
GR
,
et al.
.
Difficult thoracic lesions: CT-guided biopsy experience in 150 cases
Radiology
1988
167
457
61
PubMed
CrossRef

PubMed
Garca Ro
F
,
Daz Lobato
S
,
Pino
JM
,
Atienza
M
,
Viguer
JM
,
Villasante
C
,
et al.
.
Value of CT-guided fine needle aspiration in solitary pulmonary nodules with negative fiberoptic bronchoscopy
Acta Radiol
1994
35
478
80
PubMed
CrossRef

PubMed
Li
H
,
Boiselle
PM
,
Shepard
JO
,
Trotman-Dickenson
B
,
McLoud
TC
.
Diagnostic accuracy and safety of CT-guided percutaneous needle aspiration biopsy of the lung: comparison of small and large pulmonary nodules
AJR Am J Roentgenol
1996
167
105
9
PubMed
CrossRef

PubMed
Santambrogio
L
,
Nosotti
M
,
Bellaviti
N
,
Pavoni
G
,
Radice
F
,
Caputo
V
.
CT-guided fine-needle aspiration cytology of solitary pulmonary nodules: a prospective, randomized study of immediate cytologic evaluation
Chest
1997
112
423
5
PubMed
CrossRef

PubMed
Westcott
JL
,
Rao
N
,
Colley
DP
.
Transthoracic needle biopsy of small pulmonary nodules
Radiology
1997
202
97
103
PubMed
CrossRef

PubMed
Yankelevitz
DF
,
Henschke
CI
,
Koizumi
JH
,
Altorki
NK
,
Libby
D
.
CT-guided transthoracic needle biopsy of small solitary pulmonary nodules
Clin Imaging
1997
21
107
10
PubMed
CrossRef

PubMed
Hayashi
N
,
Sakai
T
,
Kitagawa
M
,
Kimoto
T
,
Inagaki
R
,
Ishii
Y
,
et al.
.
CT-guided biopsy of pulmonary nodules less than 3 cm: usefulness of the spring-operated core biopsy needle and frozen-section pathologic diagnosis
AJR Am J Roentgenol
1998
170
329
31
PubMed
CrossRef

PubMed
Laurent
F
,
Latrabe
V
,
Vergier
B
,
Montaudon
M
,
Vernejoux
JM
,
Dubrez
J
.
CT-guided transthoracic needle biopsy of pulmonary nodules smaller than 20 mm: results with an automated 20-gauge coaxial cutting needle
Clin Radiol
2000
55
281
7
PubMed
CrossRef

PubMed
Berquist
TH
,
Bailey
PB
,
Cortese
DA
,
Miller
WE
.
Transthoracic needle biopsy: accuracy and complications in relation to location and type of lesion
Mayo Clin Proc
1980
55
475
81
PubMed
PubMed
Wallace
JM
,
Deutsch
AL
.
Flexible fiberoptic bronchoscopy and percutaneous needle lung aspiration for evaluating the solitary pulmonary nodule
Chest
1982
81
665
71
PubMed
CrossRef

PubMed
Levine
MS
,
Weiss
JM
,
Harrell
JH
,
Cameron
TJ
,
Moser
KM
.
Transthoracic needle aspiration biopsy following negative fiberoptic bronchoscopy in solitary pulmonary nodules
Chest
1988
93
1152
5
PubMed
CrossRef

PubMed
Landreneau RJ, Hazelrigg SR, Ferson PF, Johnson JA, Nawarawong W, Boley TM, et al. Thoracoscopic resection of 85 pulmonary lesions. Ann Thorac Surg. 1992; 54:415-9; discussion 419-20. [PMID: 1510507]
Landreneau RJ, Sugarbaker DJ, Mack MJ, Hazelrigg SR, Luketich JD, Fetterman L, et al. Wedge resection versus lobectomy for stage I (T1 N0 M0) non-small-cell lung cancer. J Thorac Cardiovasc Surg. 1997; 113:691-8; discussion 698-700. [PMID: 9104978]
Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg. 1995; 60:615-22; discussion 622-3. [PMID: 7677489]
Romano
PS
,
Mark
DH
.
Patient and hospital characteristics related to in-hospital mortality after lung cancer resection
Chest
1992
101
1332
7
PubMed
CrossRef

PubMed
Mack MJ, Hazelrigg SR, Landreneau RJ, Acuff TE. Thoracoscopy for the diagnosis of the indeterminate solitary pulmonary nodule. Ann Thorac Surg. 1993; 56:825-30; discussion 830-2. [PMID: 8215658]
Harpole
DH
Jr
,
Herndon
JE
2nd
,
Young
WG
Jr
,
Wolfe
WG
,
Sabiston
DC
Jr
.
Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence
Cancer
1995
76
787
96
PubMed
CrossRef

PubMed
Bernard A. Resection of pulmonary nodules using video-assisted thoracic surgery. The Thorax Group. Ann Thorac Surg. 1996; 61:202-4; discussion 204-5. [PMID: 8561553]
Silvestri
GA
,
Handy
J
,
Lackland
D
,
Corley
E
,
Reed
CE
.
Specialists achieve better outcomes than generalists for lung cancer surgery
Chest
1998
114
675
80
PubMed
CrossRef

PubMed
Sugi
K
,
Kaneda
Y
,
Nawata
K
,
Fujita
N
,
Ueda
K
,
Nawata
S
,
et al.
.
Cost analysis for thoracoscopy: thoracoscopic wedge resection and lobectomy
Surg Today
1998
28
41
5
PubMed
CrossRef

PubMed
National Aeronautics and Space Administration. Gross Domestic Product Deflator Inflation Calculator. Accessed at www.jsc.nasa.gov/bu2/inflateGDP.html on 4 December 2002.
Executive Office of the President of the United States. Budget of the United States Government, Fiscal Year 2001: Historical Tables in spreadsheet format. Section 10: Gross Domestic Product and Implicit Outlay Deflators. Accessed at w3.access.gpo.gov/usbudget/fy2001/hist.html on 4 December 2002.
Centers for Medicare & Medicaid Services. 1999 National Physician Fee Schedule Relative Value File. Accessed at cms.hhs.gov/physicians/pfs/default.asp on 4 December 2002.
Centers for Medicare & Medicaid Services. Medical Providers Annual Review: Expanded modified MEDPAR-Hospital. Accessed at cms.hhs.gov/data/purchase/DEFAULT.asp on 4 December 2002.
Ball JK, Elixhauser A, Johantgen M. HCUP-3 Quality Indicators: Methods, Version 1.1: Outcome, Utilization, and Access Measures for Quality Improvement. Healthcare Cost and Utilization Project (HCUP-3) Research Note. Rockville, MD: Agency for Healthcare Policy and Research; 1998. AHCPR publication no. 98-0035.
Potosky
AL
,
Riley
GF
,
Lubitz
JD
,
Mentnech
RM
,
Kessler
LG
.
Potential for cancer related health services research using a linked Medicare-tumor registry database
Med Care
1993
31
732
48
PubMed
CrossRef

PubMed
United States Census Bureau. Statistical Abstract of the United States: 1999. Number 184. Section 3: Health and Nutrition. Accessed at www.census.gov/prod/99pubs/99statab/sec03.pdf on 4 December 2002.
Fryback
DG
,
Dasbach
EJ
,
Klein
R
,
Klein
BE
,
Dorn
N
,
Peterson
K
,
et al.
.
The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors
Med Decis Making
1993
13
89
102
PubMed
CrossRef

PubMed
Smith
TJ
,
Hillner
BE
,
Neighbors
DM
,
McSorley
PA
,
Le Chevalier
T
.
Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer
J Clin Oncol
1995
13
2166
73
PubMed
CrossRef

PubMed
Doubilet
P
,
Begg
CB
,
Weinstein
MC
,
Braun
P
,
McNeil
BJ
.
Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach
Med Decis Making
1985
5
157
77
PubMed
CrossRef

PubMed
Gould
MK
,
Owens
DK
.
Positron emission tomography for mediastinal staging in non-small cell lung cancer: a meta-analysis [Abstract]
Am J Respir Crit Care Med
1998
157
A256
CrossRef
Lillington
GA
,
Caskey
CI
.
Evaluation and management of solitary and multiple pulmonary nodules
Clin Chest Med
1993
14
111
9
PubMed
PubMed
Dietlein
M
,
Weber
K
,
Gandjour
A
,
Moka
D
,
Theissen
P
,
Lauterbach
KW
,
et al.
.
Cost-effectiveness of FDG-PET for the management of solitary pulmonary nodules: a decision analysis based on cost reimbursement in Germany
Eur J Nucl Med
2000
27
1441
56
PubMed
CrossRef

PubMed
Gambhir
SS
,
Shepherd
JE
,
Shah
BD
,
Hart
E
,
Hoh
CK
,
Valk
PE
,
et al.
.
Analytical decision model for the cost-effective management of solitary pulmonary nodules
J Clin Oncol
1998
16
2113
25
PubMed
CrossRef

PubMed
Pieterman
RM
,
van Putten
JW
,
Meuzelaar
JJ
,
Mooyaart
EL
,
Vaalburg
W
,
Koter
GH
,
et al.
.
Preoperative staging of non-small-cell lung cancer with positron-emission tomography
N Engl J Med
2000
343
254
61
PubMed
CrossRef

PubMed
Dwamena
BA
,
Sonnad
SS
,
Angobaldo
JO
,
Wahl
RL
.
Metastases from non-small cell lung cancer: mediastinal staging in the 1990smeta-analytic comparison of PET and CT
Radiology
1999
213
530
6
PubMed
CrossRef

PubMed
Trampert
L
,
Holle
LH
,
Berberich
R
,
Alexander
C
,
Ukena
D
,
Ruth
T
,
et al.
.
[18FDG in the primary staging of lung tumors. Results with a camera and a 511 keV collimator]
Nuklearmedizin
1995
34
79
86
PubMed
PubMed
Shreve
PD
,
Steventon
RS
,
Deters
EC
,
Kison
PV
,
Gross
MD
,
Wahl
RL
.
Oncologic diagnosis with 2-[fluorine-18]fluoro-2-deoxy-D-glucose imaging: dual-head coincidence camera versus positron emission tomographic scanner
Radiology
1998
207
431
7
PubMed
CrossRef

PubMed
Weber
W
,
Young
C
,
Abdel-Dayem
HM
,
Sfakianakis
G
,
Weir
GJ
,
Swaney
CM
,
et al.
.
Assessment of pulmonary lesions with 18F-fluorodeoxyglucose positron imaging using coincidence mode cameras
J Nucl Med
1999
40
574
8
PubMed
PubMed
Kim
S
,
Park
CH
,
Han
M
,
Hwang
S
,
Lee
C
,
Pai
M
.
The clinical usefulness of F-18 FDG coincidence PET without attenuation correction and without whole-body scanning mode in pulmonary lesions comparison with CT, MRI, and clinical findings
Clin Nucl Med
1999
24
945
9
PubMed
CrossRef

PubMed
Henschke
CI
,
McCauley
DI
,
Yankelevitz
DF
,
Naidich
DP
,
McGuinness
G
,
Miettinen
OS
,
et al.
.
Early Lung Cancer Action Project: overall design and findings from baseline screening
Lancet
1999
354
99
105
PubMed
CrossRef

PubMed
Martini N, Rusch VW, Bains MS, Kris MG, Downey RJ, Flehinger BJ, et al. Factors influencing ten-year survival in resected stages I to IIIa non-small cell lung cancer. J Thorac Cardiovasc Surg. 1999; 117:32-6; discussion 37-8. [PMID: 9869756]
U.S. Department of Health and Human Services, Public Health Service. Interpolated Abridged Life Table, United States, 1996. Accessed at www.cdc.gov/nchs/datawh/statab/unpubd/mortabs/lewk2.htm on 4 December 2002.
Nathan
MH
,
Collins
VP
,
Adams
RA
.
Differentiation of benign and malignant pulmonary nodules by growth rate
Radiology
1962
79
221
32
CrossRef

PubMed
Geddes
DM
.
The natural history of lung cancer: a review based on rates of tumour growth
Br J Dis Chest
1979
73
1
17
PubMed
CrossRef

PubMed
Brown
BW
,
Atkinson
EN
,
Bartoszynski
R
,
Thompson
JR
,
Montague
ED
.
Estimation of human tumor growth rate from distribution of tumor size at detection
J Natl Cancer Inst
1984
72
31
8
PubMed
CrossRef

PubMed
Beck
JR
,
Kassirer
JP
,
Pauker
SG
.
A convenient approximation of life expectancy (the DEALE). I. Validation of the method
Am J Med
1982
73
883
8
PubMed
CrossRef

PubMed
Beck
JR
,
Pauker
SG
,
Gottlieb
JE
,
Klein
K
,
Kassirer
JP
.
A convenient approximation of life expectancy (the DEALE). II. Use in medical decision-making
Am J Med
1982
73
889
97
PubMed
CrossRef

PubMed
Steele
JD
,
Kleitsch
WP
,
Dunn
JE
Jr
,
Buell
P
.
Survival in males with bronchogenic carcinomas resected as asymptomatic solitary pulmonary nodules
Ann Thorac Surg
1966
2
368
76
PubMed
CrossRef

PubMed
Jackman
RJ
,
Good
CA
,
Clagett
OT
,
Woolner
LB
.
Survival rates in peripheral bronchogenic carcinomas up to four centimeters in diameter presenting as solitary pulmonary nodules
J Thorac Cardiovasc Surg
1969
57
1
8
PubMed
PubMed
Steele
JD
.
The solitary pulmonary nodule. Report of a cooperative study of resected asymptomatic solitary pulmonary nodules in males
J Thorac Cardiovasc Surg
1963
46
21
39
PubMed
Patz
EF
Jr
,
Rossi
S
,
Harpole
DH
Jr
,
Herndon
JE
,
Goodman
PC
.
Correlation of tumor size and survival in patients with stage IA non-small cell lung cancer
Chest
2000
117
1568
71
PubMed
CrossRef

PubMed
Kent
DL
,
Haynor
DR
,
Larson
EB
,
Deyo
RA
.
Diagnosis of lumbar spinal stenosis in adults: a metaanalysis of the accuracy of CT, MR, and myelography
AJR Am J Roentgenol
1992
158
1135
44
PubMed
CrossRef

PubMed
Owens
DK
,
Holodniy
M
,
McDonald
TW
,
Scott
J
,
Sonnad
S
.
A meta-analytic evaluation of the polymerase chain reaction for the diagnosis of HIV infection in infants
JAMA
1996
275
1342
8
PubMed
CrossRef

PubMed
Kubota
K
,
Matsuzawa
T
,
Fujiwara
T
,
Abe
Y
,
Tada
M
,
Ido
T
,
et al.
.
[Recent advances of positron emission tomography and CT scan for the diagnosis of early cancer]
Nippon Rinsho
1989
47
1037
43
PubMed
PubMed
Kelsey JL, Whittemore AS, Evans AS, Thompson WD. Methods in Observational Epidemiology. 2nd ed. vol. 26. New York: Oxford Univ Pr; 1996.
Swensen
SJ
,
Brown
LR
,
Colby
TV
,
Weaver
AL
.
Pulmonary nodules: CT evaluation of enhancement with iodinated contrast material
Radiology
1995
194
393
8
PubMed
CrossRef

PubMed
Yamashita
K
,
Matsunobe
S
,
Tsuda
T
,
Nemoto
T
,
Matsumoto
K
,
Miki
H
,
et al.
.
Solitary pulmonary nodule: preliminary study of evaluation with incremental dynamic CT
Radiology
1995
194
399
405
PubMed
CrossRef

PubMed
Swensen
SJ
,
Brown
LR
,
Colby
TV
,
Weaver
AL
,
Midthun
DE
.
Lung nodule enhancement at CT: prospective findings
Radiology
1996
201
447
55
PubMed
CrossRef

PubMed
Potente
G
,
Iacari
V
,
Caimi
M
.
The challenge of solitary pulmonary nodules: HRCT evaluation
Comput Med Imaging Graph
1997
21
39
46
PubMed
CrossRef

PubMed
Swensen
SJ
,
Viggiano
RW
,
Midthun
DE
,
Mller
NL
,
Sherrick
A
,
Yamashita
K
,
et al.
.
Lung nodule enhancement at CT: multicenter study
Radiology
2000
214
73
80
PubMed
CrossRef

PubMed
Yankelevitz
DF
,
Henschke
CI
,
Koizumi
J
,
Libby
DM
,
Topham
S
,
Altorki
N
.
CT-guided transthoracic needle biopsy following indeterminate fiberoptic bronchoscopy in solitary pulmonary nodules
Clin Imaging
1998
22
7
10
PubMed
CrossRef

PubMed
Yim
AP
,
Ko
KM
,
Chau
WS
,
Ma
CC
,
Ho
JK
,
Kyaw
K
.
Video-assisted thoracoscopic anatomic lung resections. The initial Hong Kong experience
Chest
1996
109
13
7
PubMed
CrossRef

PubMed
Loscertales
J
,
Jimenez-Merchan
R
,
Arenas-Linares
C
,
Giron-Arjona
JC
,
Congregado-Loscertales
M
.
The use of videoassisted thoracic surgery in lung cancer: evaluation of resectability in 296 patients and 71 pulmonary exeresis with radical lymphadenectomy
Eur J Cardiothorac Surg
1997
12
892
7
PubMed
CrossRef

PubMed
Brown
WT
.
Video-assisted thoracic surgery: the Miami experience
Semin Thorac Cardiovasc Surg
1998
10
305
12
PubMed
CrossRef

PubMed
Hermansson
U
,
Konstantinov
IE
,
Arn
C
.
Video-assisted thoracic surgery (VATS) lobectomy: the initial Swedish experience
Semin Thorac Cardiovasc Surg
1998
10
285
90
PubMed
CrossRef

PubMed
Kaseda
S
,
Aoki
T
,
Hangai
N
.
Video-assisted thoracic surgery (VATS) lobectomy: the Japanese experience
Semin Thorac Cardiovasc Surg
1998
10
300
4
PubMed
CrossRef

PubMed
Lewis
RJ
,
Caccavale
RJ
.
Video-assisted thoracic surgical non-rib spreading simultaneously stapled lobectomy (VATS[n]SSL)
Semin Thorac Cardiovasc Surg
1998
10
332
9
PubMed
CrossRef

PubMed
McKenna
RJ
Jr
,
Wolf
RK
,
Brenner
M
,
Fischel
RJ
,
Wurnig
P
.
Is lobectomy by video-assisted thoracic surgery an adequate cancer operation?
Ann Thorac Surg
1998
66
1903
8
PubMed
CrossRef

PubMed
Roviaro
G
,
Varoli
F
,
Vergani
C
,
Maciocco
M
.
Video-assisted thoracoscopic surgery (VATS) major pulmonary resections: the Italian experience
Semin Thorac Cardiovasc Surg
1998
10
313
20
PubMed
CrossRef

PubMed
Walker
WS
.
Video-assisted thoracic surgery (VATS) lobectomy: the Edinburgh experience
Semin Thorac Cardiovasc Surg
1998
10
291
9
PubMed
CrossRef

PubMed
Yim
AP
,
Izzat
MB
,
Liu
HP
,
Ma
CC
.
Thoracoscopic major lung resections: an Asian perspective
Semin Thorac Cardiovasc Surg
1998
10
326
31
PubMed
CrossRef

PubMed
Miller DL, Allen MS, Trastek VF, Deschamps C, Pairolero PC. Videothoracoscopic wedge excision of the lung. Ann Thorac Surg. 1992; 54:410-3; discussion 413-4. [PMID: 1510506]
Hau
T
,
Frster
E
,
Gandawidjaja
L
,
Heemken
R
.
Thoracoscopic pulmonary surgery: indications and results
Eur J Surg
1996
162
23
8
PubMed
PubMed
Jancovici
R
,
Lang-Lazdunski
L
,
Pons
F
,
Cador
L
,
Dujon
A
,
Dahan
M
,
et al.
.
Complications of video-assisted thoracic surgery: a five-year experience
Ann Thorac Surg
1996
61
533
7
PubMed
CrossRef

PubMed
Mitruka
S
,
Landreneau
RJ
,
Mack
MJ
,
Fetterman
LS
,
Gammie
J
,
Bartley
S
,
et al.
.
Diagnosing the indeterminate pulmonary nodule: percutaneous biopsy versus thoracoscopy
Surgery
1995
118
676
84
PubMed
CrossRef

PubMed
Asamura
H
,
Nakayama
H
,
Kondo
H
,
Tsuchiya
R
,
Naruke
T
.
Thoracoscopic evaluation of histologically/cytologically proven or suspected lung cancer: a VATS exploration
Lung Cancer
1997
16
183
90
PubMed
CrossRef

PubMed
Dales
RE
,
Stark
RM
,
Raman
S
.
Computed tomography to stage lung cancer. Approaching a controversy using meta-analysis
Am Rev Respir Dis
1990
141
1096
101
PubMed
CrossRef

PubMed
Shah
R
,
Sabanathan
S
,
Richardson
J
,
Mearns
AJ
,
Goulden
C
.
Results of surgical treatment of stage I and II lung cancer
J Cardiovasc Surg (Torino)
1996
37
169
72
PubMed
PubMed
Cutler
DM
,
McClellan
M
,
Newhouse
JP
,
Remler
D
.
Are medical prices declining? Evidence from heart attack treatments
Quarterly Journal of Economics
1998
113
991
1024
CrossRef
Tengs
TO
,
Wallace
A
.
One thousand health-related quality-of-life estimates
Med Care
2000
38
583
637
PubMed
CrossRef

PubMed
Dales
RE
,
Blanger
R
,
Shamji
FM
,
Leech
J
,
Crpeau
A
,
Sachs
HJ
.
Quality-of-life following thoracotomy for lung cancer
J Clin Epidemiol
1994
47
1443
9
PubMed
CrossRef

PubMed
Zieren
HU
,
Mller
JM
,
Hamberger
U
,
Pichlmaier
H
.
Quality of life after surgical therapy of bronchogenic carcinoma
Eur J Cardiothorac Surg
1996
10
233
7
PubMed
CrossRef

PubMed
Cummings
SR
,
Lillington
GA
,
Richard
RJ
.
Estimating the probability of malignancy in solitary pulmonary nodules. A Bayesian approach
Am Rev Respir Dis
1986
134
449
52
PubMed
PubMed
Gurney
JW
,
Lyddon
DM
,
McKay
JA
.
Determining the likelihood of malignancy in solitary pulmonary nodules with Bayesian analysis. Part II. Application
Radiology
1993
186
415
22
PubMed
CrossRef

PubMed
Swensen
SJ
,
Silverstein
MD
,
Edell
ES
,
Trastek
VF
,
Aughenbaugh
GL
,
Ilstrup
DM
,
et al.
.
Solitary pulmonary nodules: clinical prediction model versus physicians
Mayo Clin Proc
1999
74
319
29
PubMed
CrossRef

PubMed
Siegel
JE
,
Weinstein
MC
,
Torrance
GW
.
Cost-Effectiveness in Health and Medicine
New York
Oxford Univ Pr
1996
276
303
Hunink
MG
,
Bult
JR
,
de Vries
J
,
Weinstein
MC
.
Uncertainty in decision models analyzing cost-effectiveness: the joint distribution of incremental costs and effectiveness evaluated with a nonparametric bootstrap method
Med Decis Making
1998
18
337
46
PubMed
CrossRef

PubMed

Figure 1.

Recommended sequence of diagnostic testing in patients who are at average risk for surgical complications, according to pretest probability and the results of computed tomography (CT).topbottom

Figure 2.

Suggested algorithm for clinical management of patients with solitary pulmonary nodules who are at average risk for surgical complications.CT

Appendix (Figure 1).

Decision model.ACTFDG-PETBCD

Appendix (Figure 2).

Decision model subtrees.

Appendix (Figure 3).

Markov model.

Appendix (Figure 4).

Observed and modeled survival for patients with local, regional, and distant lung cancer.SEER

Appendix (Figure 5).

Distribution of tumor doubling times and corresponding probabilities of disease progression during the observation period.black circles

Appendix (Figure 6).

Summary receiver-operating characteristic (ROC) curve for positron emission tomography with 18-fluorodeoxyglucose (FDG-PET).dotted linesblack squareblack circle

Appendix (Figure 7).

Summary receiver-operating characteristic (ROC) curve for computed tomography (CT).dotted lines

Appendix (Figure 8).

Health care costs for patients with malignant pulmonary nodules.black circlesblack squaresblack triangles

Appendix (Figure 9).

Appendix (Figure 10).

Table 1. Expected Costs, Quality-Adjusted Life-Years, and Incremental Cost-Effectiveness Ratios for Nondominated Strategies in Patients with Low, Intermediate, and High Pretest Probability of Malignancy

Table 2. Recommendations on the Use of Computed Tomography, Positron Emission Tomography with 18-Fluorodeoxyglucose, Watchful Waiting, Transthoracic Needle Biopsy, and Surgery

Appendix Table 2. Alternative Strategies for Management of Patients with Solitary Pulmonary Nodules

Appendix Table 3. MEDLINE Search for Studies of Positron Emission Tomography with 18-Fluorodeoxyglucose

Appendix Table 4. Studies of Positron Emission Tomography with 18-Fluorodeoxyglucose for Pulmonary Nodule Diagnosis

Appendix Table 5. Studies of Computed Tomography Densitometry for Diagnosis of Pulmonary Nodules and Mass Lesions

Appendix Table 6. Studies of High-Resolution Computed Tomography for Pulmonary Nodule Diagnosis

Appendix Table 7. Studies of Dynamic Computed Tomography with Nodule Enhancement

Appendix Table 8. Studies of Computed TomographyGuided Needle Biopsy for Pulmonary Nodule Diagnosis

Appendix Table 9. Expected Costs, Quality-Adjusted Life-Years, and Incremental Cost-Effectiveness Ratios in Patients with Low Pretest Probability (26%) and Average Risk for Surgical Complications

Appendix Table 10. Expected Costs, Quality-Adjusted Life-Years, and Incremental Cost-Effectiveness Ratios in Patients with Low Pretest Probability (26%) and High Risk for Surgical Complications

Appendix Table 11. Expected Costs, Quality-Adjusted Life-Years, and Incremental Cost-Effectiveness Ratios in Patients with Intermediate Pretest Probability (55%) and Average Risk for Surgical Complications

Appendix Table 12. Expected Costs, Quality-Adjusted Life-Years, and Incremental Cost-Effectiveness Ratios in Patients with Intermediate Pretest Probability (55%) and High Risk for Surgical Complications

Appendix Table 13. Expected Costs, Quality-Adjusted Life-Years, and Incremental Cost-Effectiveness Ratios in Patients with High Pretest Probability (79%) and Average Risk for Surgical Complications

Appendix Table 14. Expected Costs, Quality-Adjusted Life-Years, and Incremental Cost-Effectiveness Ratios in Patients with High Pretest Probability (79%) and High Risk for Surgical Complications

This feature is available only to Registered Users

Subscribe/Learn More

PDF

Not Available